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Abstract 
Host detection of foreign pathogens can trigger both innate and adaptive immune 
responses; CD4+ T helper (Th) cells play a critical role in the latter. Upon encountering 
its cognate antigen and receiving appropriate co-stimulatory signals, a naïve CD4+ Th 
cell can differentiate into a variety of effector subsets that include, but are not limited to, 
CD4+ Th1, Th2, Th17, Tfh, and iTregs. This dissertation focuses on the regulatory 
circuitry that enables the differentiation of distinct CD4+ Th cell lineages; concentrating 
on the role of microRNA (miRNA) in this T cell fate decision. Experimentally, in vitro 
polarization of primary murine CD4+ Th cells by addition of exogenous cytokines is used 
to decipher the molecular and signaling events that control the differentiation process of 
each subset. Examination of Th1, Th2, and Th17 cells deficient in Signal Transducers 
and Activators of Transcription (STAT) signaling, reveals the critical function of these 
transcription factors in inducing expression of non-coding RNA.  
 Focusing on the CD4+ Th17 cell subset, a key role for STAT3 is identified in 
regulating the expression of miR-29 and miR-155. We find that miR-29 expression in 
Th17 cells prevents aberrant cytokine expression, and this miRNA has a further role in 
the in vivo generation of pathogenic Th17 cells during autoimmune disease. Moreover, 
we show that miR-155 promotes Th17 cytokine expression by altering the chromatin 
state through the inhibition of Jarid2 expression. In the context of embryonic stem cells, 
Jarid2 recruits the Polycomb Repressive Complex 2 (PRC2) to epigenetically silence key 
developmental genes by catalyzing the trimethylation of H3K27. We find that high 
expression of miR-155 in Th17 cells alleviates Jarid2-PRC2 inhibition of genes encoding 
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Th17 signature cytokines. Thus, miR-155 targeting of Jarid2 favors a more open 
chromatin state at both cytokine loci and genes promoting Th17 cell development. 
 Through collaboration with the National Center for Advancing Translational 
Sciences (NCATS), the translational aspects of these research questions were 
investigated. MiR-155 and Th17 cells are highly expressed in many autoimmune diseases 
and Th17 cells have a detrimental role in such diseases. By examining the molecular 
networks involving miRNAs in CD4+ Th cell development, our goal is to find new drugs 
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1.1 CD4+ T helper cell differentiation and function 
 The immune system is made of various cell types whose function is to protect the 
host from infection by foreign pathogens while sparing self-tissues. This protection 
involves a dynamic and highly coordinated process that includes 1) recognition of an 
infectious agent, 2) initiation and progression of an appropriate response to eliminate the 
foreign agent, 3) the ability to self regulate, and 4) acquisition of immunological memory 
to combat pathogen re-exposure (Murphy et al., 2008). To accomplish this process, the 
immune system is comprised of a vast array of cell types and molecules that constitute 
two branches, each with unique properties and function. The innate immune system 
represents a “first line of defense” against foreign pathogens and is made up of 
macrophages, neutrophils, basophils, eosinophils, mast cells, natural killer cells, and 
dendritic cells. Although innate immunity provides an early and broad inflammatory 
response to bacteria, viruses, and fungi, these responses to a foreign pathogen are not 
tailored and are recognized through a series of common receptors. A key feature of innate 
immunity is the ability to activate the second branch of the immune response in order to 
specialize a response and retain immunological memory (Murphy et al., 2008).  
 The adaptive immune system is composed of B and T lymphocytes that enable a 
highly specialized and specific response to pathogens. This type of tailored response is 
due to unique receptors, B cell receptors (BCR) and T cell receptors (TCR) on the surface 
of B and T cells, respectively, that are able to recognize a potentially unlimited array of 
agents. Activation of B cells via their BCR results in a humoral immune response: the 
release of a variety of soluble antibodies that are able to bind to and neutralize infectious 
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pathogens. Although B cells are critical for immunity, this thesis focuses on T cell 
development. 
T cells represent a functionally diverse population of immune cells that include 
both CD8+ and CD4+ T cells. After development within the thymus, CD8+ and CD4+ T 
cells emigrate throughout the body as antigen-inexperienced, naïve T cells. Such naïve T 
cells continuously circulate from the bloodstream through secondary lymphoid tissues, 
sampling antigens being presented by antigen-presenting cells. During an immune 
response, a naïve T cell expressing a particular TCR may encounter a foreign pathogen in 
the context of peptide/MHC (signal 1). CD8+ T cells recognize peptides presented in the 
context of major histocompatibility complex (MHC) class I and are typically classified as 
cytotoxic T lymphocytes due to their ability to recognize and eliminate virally infected 
cells and cancerous cells via the release of a variety of soluble mediators, including 
cytokines and lytic granules. Focusing on the content of this thesis research, CD4+ T cells 
recognize peptides presented in the context of MHC class II on the surface of antigen 
presenting cells and are activated to differentiate into multiple “T helper” (Th) cell 
subsets that, in turn, help activate other cells of the immune system.  
In addition to signal 1, a second stimulus (signal 2) is required to enable the T cell 
to proliferate and proceed with its functional role. Without appropriate co-stimulation, the 
T cell is rendered functionally inactivated and anergic. This secondary signal is also an 
important check for preventing inappropriate activation that may lead to autoimmunity. A 
unique feature of adaptive immunity is the ability to generate immunological memory. 
Following an immune response, a portion of B and T cells are retained as long-lived 
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memory cells that are able to rapidly respond upon pathogen re-exposure (Murphy et al., 
2008).   
 The differentiation of CD4+ T cells into various Th cell subsets is highly 
dependent on the cytokine milieu during an inflammatory response. Contingent on the 
environment, activated CD4+ T cells can develop into Th lineages that are defined 
primarily by the expression of specific master transcription factors, which initiate distinct 
differentiation programs affecting cell function and cytokine production. The various 
CD4+ Th cell subsets include Th1, which express the transcription factor T-bet and the 
signature cytokine interferon (IFN)γ; Th2, which are characterized by Gata3 expression 
and interleukin (IL)-4 production; Th17, which express RAR-related orphan receptor 
(ROR)γt and produce IL-17; T follicular helper cells (Tfh), which are defined by Bcl6 
expression and IL-21 production; and regulatory T cells (Treg), which express the 
transcription factor Foxp3 and produce IL-10 (Zhu et al., 2010). Each CD4+ Th cell 
subset and their respective cytokines provide a highly specialized immunological defense 
that protects the host from various foreign pathogens. For example, a Th1-biased immune 
response with prominent IFNγ production is tailored to fight and eliminate intracellular 
infection resulting from viruses or parasites (Awasthi and Kuchroo, 2009). Infection with 
extracellular pathogens, such as fungal infection, results in a response dominated by Th-
17 cells (Awasthi and Kuchroo, 2009).  
The central role of CD4+ Th cells in the context of an immune response is 
highlighted in HIV-induced acquired immunodeficiency syndrome (AIDS), where there 
is a severe reduction of CD4+ T cells and concomitant predisposition to opportunistic 
infections (Douek et al., 2003). Although protective in nature, improper or chronic 
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activation of CD4+ Th cells can cause autoimmunity. Furthermore, defective 
differentiation of CD4+ T cells also contributes to severe disease states, such as the 
immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome that 
is evident as a result of mutations in the FOXP3 gene (Bennett et al., 2001; Brunkow et 
al., 2001; Wildin et al., 2001). Thus, understanding the molecular basis of CD4+ Th cell 
differentiation will provide key information into subset specification and facilitate the 
design of more effective strategies for targeting autoimmunity or opportunistic infections. 
 The molecular development of distinct CD4+ Th cell lineages is orchestrated by a 
regulatory network that integrates signals from the TCR-MHC interaction, co-stimulatory 
ligands, and the extracellular cytokine milieu in order to achieve a series of programmed 
gene expression changes (Figure 1). For example, during the differentiation program of 
Th1 cells, engagement of IL-12 and IFNγ with their corresponding receptors on the 
surface of naïve CD4+ T cells is required for the initial commitment and corresponding 
phosphorylation of signal transducer and activator of transcription (STAT)4 and STAT1. 
Following phosphorylation, STAT4 and STAT1 homodimerize and translocate to the 
nucleus where they induce the transcription of key Th1-associated genes, including T-bet 
and IFNγ. The Th2 differentiation program involves binding of IL-4 to the IL-4 receptor 
(IL-4R), which triggers STAT6 activation and subsequent activation of GATA3 and IL-4. 
The presence of IL-6 and transforming growth factor (TGFβ) initiates STAT3 activation 
and translocation to the nucleus to induce the expression of RORγt and IL-17. Lastly, 
TGFβ is able to stimulate the up-regulation of Foxp3 and the Treg differentiation 
program  (Figure 1) (Egwuagu, 2009).  
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Figure 1. Outline of CD4+ T helper cell differentiation. During the initial activation of 
CD4+ lymphocytes, antigen-presenting dendritic cells secrete a variety of cytokines that 
instruct the naïve T cell to initiate one of several Th cell developmental pathways leading 
to the Th1, Th2, Th17, or Treg cell lineages. Each CD4+ Th cell subset produces a range 
of signature cytokines that mediates its distinct immunoregulatory functions (Reprinted 
from Cytokine, 47(3), Charles Egwuagu, STAT3 in CD4+ T helper Cell differentiation 






mediated costimulatory signals (NF-jB, PI3K/AKT) that promote
lymphocyte survival and clonal expansion [41–43]. Prolonged stim-
ulation by strong TCR/costimulatory signals induces sustained acti-
vation of NFAT, AP1 and NF-jBwhile inhibiting expression of Foxp3
(Forkhead box P3 transcription factor). Conversely, signals of low
TCR signaling strength or premature termination/blockade of TCR/
CD28 signals confer sustained Foxp3 expression and promote unre-
sponsiveness or anergy [39,40]. Thus, increase in NFAT, NF-jB and
AP1 favors development into the rapidly proliferating Th1 and Th17
effector subsets while the Treg phenotype is characterized by in-
crease in Foxp3 expression, impaired calciummobilization, reduced
Ras-Erk-AP1 signaling and lower proliferative capacity [44]. Inter-
estingly, recent reports indicate that NFAT regulates T cell activa-
tion and anergy by forming cooperative complexes with either
AP1 or Foxp3, respectively [45]. Commitment to effector T cell line-
age would therefore be favored by net increases in homeostatic
NFAT:AP1 complexes while Treg development and tolerogenic re-
sponses would derive from enhanced NFAT:Foxp3 partnering
[45]. It is therefore of note, that Th17 or iTreg differentiation pro-
gram has obligatory requirement for TGF-b1, a potent inducer of
Foxp3. Stimulation of naïve T cells in TGF-b rich environment re-
sults in the production of IL-2 and activation of TGF-b1 signal trans-
duction pathway. Convergence of the STAT5 and SMAD signals on
the differentiating cells initiates the development of a Treg/Th17
precursor cell type characterized by expression of Foxp3 and reti-
noic acid-related orphan receptor (ROR-ct) transcription factors
(see Fig. 3). Terminal differentiation of the Treg/Th17 precursor into
either the Th17 or iTreg lineage is thought to depend in part on cell-
extrinsic factors such as cytokines in the microenvironment that
may alter the relative abundance of Foxp3 and ROR-ct [46,47].
Although stimulation of naive T cells in TGF-b1-rich environment
is sufficient to induce terminal differentiation into iTreg, produc-
tion of IL-6 during inflammation and its activation of STAT3, result
in upregulation of RORct and skewing of the developmental pro-
gram towards Th17 lineage [46,48,49]. Thus, the STAT3 pathway
is situated at the juncture where Th17 and iTreg developmental
programs diverge. Sustained PI3K/Akt/mTOR signaling that occurs
in chronic inflammatory conditions has been shown to inhibit
TGF-b signaling and Foxp3 expression [50], suggesting that stabil-
ization of NFAT:AP1 at expense of NFAT:Foxp3 complexes may also
promote Th17 lineage choice.
3.2. Regulatory T cell developmental program
Regulatory T cells are a dedicated subset of T cells that control
responses of effector T cells and maintain peripheral tolerance
[51,52]. The best-characterized Tregs are the naturally occurring
Treg (nTreg) that arise from the thymus and the inducible or acti-
vated Treg (iTreg) that are generated in the periphery from conven-
tional CD4+CD25!Foxp3! T cells during inflammation [51,52]. Both
are characterized by constitutive expression of high levels of CD25
and Foxp3. The Foxp3 gene is essential for development and main-
tenance of Treg cells in the periphery and is induced by TGF-b1 and
IL-2 through SMAD3- and STAT-5-dependent mechanisms (see
Fig. 3) [53,54]. However, the Foxp3 promoter also contains STAT3
binding motif through which IL-6 can conceivably attenuate its
expression in inflammatory conditions [55,56]. Indeed mutual
antagonism between Foxp3 and ROR-ct results in preferential
expression of Foxp3 in absence of STAT3 signaling, favoring iTreg
development [49]. Stabilization and acquisition of functional com-
petence of the iTreg phenotype derives from upregulation of Treg
markers (CTLA-4, CD25, TLR10), reduced capacity for IL-2 secretion
and persistence of a state of unresponsiveness to TCR or CD28 sig-
nals [57]. The Treg subset also comprise of regulatory T cells that
do not express Foxp3 and includes: (i) Type 1 regulatory T cells
(Tr1) generated from naive or effector CD4+ T cells under chronic
stimulation driven by IL-10-secreting immature or tolerogenic
DCs [58]; (ii) TGF-b-producing regulatory T cells induced by oral
tolerance (Th3) and (iii) IL-21-producing CD4+ follicular helper T
cells (TFH) that stimulate differentiation of B cells [59]. Despite
their current designation as a distinct T cell subset, Tregs do not
strictly satisfy criteria for consideration as a separate T helper line-
Fig. 2. Outline of T-helper-cell differentiation. During the initial activation of CD4+ lymphocyte, the antigen-presenting dendritic cells secrete a variety of cytokines that
instruct the naïve T cell to activate one of several alternative T helper cell developmental pathways leading to Th1, Th2, Th17 or Treg lineage. Each T helper phenotype
produces its signature cytokines that mediate its distinct immunoregulatory functions.
C.E. Egwuagu / Cytokine 47 (2009) 149–156 151
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1.2 The transcription factor network that regulates Th17 cell development 
The well-defined function and characterization of different CD4+ Th cell lineages 
provides the ideal opportunity to study the effect of transcription factors whose gene 
expression changes confer unique cellular functions (Zhu et al., 2010). Recently, the 
transcription factor network necessary for Th17 cell development was identified (Fujita-
Sato et al., 2011; Li et al., 2012; Yosef et al., 2013b). This network includes STAT3, 
interferon regulatory factor (IRF)4 and basic leucine zipper transcription factor, ATF-like 
(BATF) that are expressed early in the Th17 cell differentiation program and drive the 
induction of the Rorc gene (encoding the transcription factor RORγt) (Ciofani et al., 
2012; Yosef et al., 2013b). The induction of RORγt expression, in concert with other 
transcription factors such as RORα, c-Maf and the aryl hydrocarbon receptor (AHR), 
promotes the expression of the signature Th17 cytokines that include IL-17a, IL-17f, IL-













Figure 2.  A transcription factor network promotes Th17 cell development and 
function.  Upon the initial activation of naïve CD4+ T cells, STAT3, BATF and IRF4 
induce the expression of key transcription factors and genes that promote the 
differentiation of CD4+ T cells towards a Th17 lineage. Following the induction of 
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1.3 Therapeutic potential of targeting Th17 cells in chronic inflammatory 
 diseases 
 Amongst the critical roles of CD4+ T cells in host defense and protection, Th17 
cells constitute a key lineage involved in mucosal defense. In response to pathogens Th17 
cells mount an inflammatory response through the secretion of pro-inflammatory 
cytokines. When this pro-inflammatory function becomes unregulated, it can also be a 
major contributor to autoimmune inflammatory diseases. For example, Th17 associated 
molecules, such as IL-17a and IL-22, are protective against an array of pathogenic 
organisms, such as the Gram-negative bacteria Escherichia coli (Shibata et al., 2007) and 
Salmonella enterica enteritidis (Schulz et al., 2008), as well as the fungus Candida 
albicans (Huang et al., 2004; O'Connor et al., 2010). The protective potential of Th17 
cells is due in large part to their induction of antimicrobial peptides and the direct 
regulation of neutrophils via IL-17 and IL-22 (O'Connor et al., 2010). In addition to their 
ability to provide host defense, IL-17 and IL-22 also have secondary roles in the control 
of inflammatory damage. IL-22 plays a prominent role during tissue regeneration, 
particularly at mucosal surfaces found in the lungs and intestine. The activation of IL-22 
increases epithelial proliferation, enhances mucus-associated proteins important in 
forming the mucus layer, and induces expression of matrix metalloproteinases (MMPs) to 
allow epithelial cell migration and apoptosis (Witte et al., 2010).  
 Yet, the same inflammatory and tissue regenerative properties of Th17 cells that 
are necessary for host defense can lead to undesirable and adverse conditions, including 
autoimmune disease and cancer. For example, in autoimmune conditions such as 
psoriasis, IL-22 promotes keratinocyte migration leading to hyperplasia and thickening of 
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the epidermis (Boniface et al., 2005; Kebir et al., 2007; Zheng et al., 2007). In 
rheumatoid arthritis, Th17 cells lead to bone erosion and cartilage proteoglycan loss (Sato 
et al., 2006; van den Berg and Miossec, 2009). Likewise, in multiple sclerosis, Th17 
lymphocytes have the capacity to pass the blood brain barrier and promote central 
nervous system inflammation, through the production of both IL-17 and IL-22, which 
results in neuronal loss (Kebir et al., 2007). In addition to the damaging effects of Th17 
cells in inflammatory diseases, it was found that through an IL-22 axis, chronic mucosal 
inflammation and tissue damage predisposes patients to the development of colorectal 
cancer (Huber et al., 2012).  
 Although CD4+ Th17 cells are protective in host defense, this same lineage is 
highly pathogenic during autoimmune disease. As such, the ability to find therapeutic 
treatments that limit inflammatory pathology without inducing generalized 
immunosuppression is key to improving Th17 autoimmune therapy. Thus far, small 
molecule screens to find Th17 inhibitors have identified Halofuginone (Sundrud et al., 
2009), SR1001 (Solt et al., 2011), and Digoxin (Huh et al., 2011) as potential Th17 
therapeutic candidates in mice. SR1001 and Digoxin were found to compete with natural 
agonists of the master transcription factor for Th17 development, RORγt, thus reducing 
its transcriptional activity and suppressing autoimmunity (Figure 3) (Fujita-Sato et al., 
2011; Jetten, 2011). These therapeutics work, but are not ideal because they prevent Th17 
development and therefore loss of a major component of the immune system. For this 
reason, finding small molecule inhibitors that do not affect Th17 differentiation but do 
affect cytokine production are of great interest.  
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Figure 3. Th17 cell differentiation and therapeutic candidates for autoimmune 
disorders. In response to antigen encounter on the surface of antigen-presenting cells 
(and in the presence of IL-6 and TGF-β), naïve CD4+ T cells differentiate into Th17 cells. 
This event is associated with expression of the nuclear receptors RORγt and RORα. 
These receptors, particularly RORγt, are required for Th17 cell differentiation and for the 
expression of IL-23R and IL-17a. Two studies have shown that digoxin (Huh et al., 2011) 
and SR1001 (Solt et al., 2011) bind to RORγt, possibly by competing with the natural 
agonists of is receptor. By inhibiting the recruitment of co-activators and promoting the 
recruitment of co-repressors, these antagonists reduce RORγt transcriptional activity, 
Th17 cell differentiation and IL-17 production, and delay the onset and reduce the 
severity of autoimmune disease in mice (Reprinted by permission from Macmillan 
Publishers Ltd: Nature, Jetten, 2011). http://www.nature.com/nature/index.html  
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1.4 Non-coding RNA regulation of gene expression 
 Although a large amount of research has been dedicated to the 
transcriptional factor network necessary for proper Th17 cell development, the roles of 
chromatin regulators and microRNA (miRNA) in this process have remained less well 
understood. To identify chromatin signatures in CD4+ Th cell development, global 
mapping of ‘active’ H3K4me3 and ‘inactive’ H3K27me3 in T cells was conducted (Wei 
et al., 2009). This work revealed epigenetic patterns that govern Th cell lineage 
specificity and suggests mechanisms other than transcription factors may command Th 
cell specificity (Wei et al., 2009). However, the exact mechanism by which transcription 
factors and the epigenetic programs work together remains unclear. One example of the 
interdependence between these two regulatory systems is seen with the requirement of 
STATs for proper P300 and H3K4me3 deposition in the Th1 and Th2 cell lineages 
(Vahedi et al., 2012). Furthermore, we now know that ablation of Dicer, an RNAse III 
enzyme required for the generation of mature miRNA, results in impaired T cell 
development (Muljo et al., 2005) and suggests an important role for the Dicer-dependent 
miRNA pathway in controlling T cell development. These findings support the idea that 
the roles of miRNA and chromatin regulators should be analyzed in conjunction with 
transcriptional networks in T cells.  
 MiRNA are evolutionarily-conserved, small, non-coding RNA (ncRNA) of 
approximately 21-24nt that control gene expression at the post-transcriptional level. A 
miRNA gene is first transcribed by RNA polymerase II into primary RNA transcripts 
(primary miRNA) that are recognized and processed by the ribonuclease III enzyme, 
Drosha in the nucleus (Figure 4A) (Baumjohann and Ansel, 2013). The processed 
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miRNA (precursor miRNA) is then exported to the cytoplasm where Dicer further 
processes it to the mature form (Figure 4A) (Baumjohann and Ansel, 2013). By guiding 
the Argonaute (Ago) protein complex (miRISC) to the complementary Watson-Crick 
base pairing of a target mRNA, a single stranded miRNA alters expression of the target 
mRNA by translational repression and/or destabilization (Figure 4A) (Baumjohann and 
Ansel, 2013).  The importance of miRNA in CD4+ Th cells is highlighted by genetic 
ablation of key molecules of the miRNA biogenesis resulting in impaired T cell 
proliferation, apoptosis, and aberrant cytokine expression (Figure 4B) (Baumjohann and 
Ansel, 2013; Chong et al., 2008; Muljo et al., 2005; Steiner et al., 2011).  
 A number of miRNA have been implicated in the regulation of T cell 
differentiation and function (Baumjohann and Ansel, 2013; Jeker and Bluestone, 2013). 
Among these, miR-155 was the first miRNA linked to CD4+ T cell differentiation based 
on its impact on Th2, Th17 and Treg cell development (Lu et al., 2009; O'Connell et al., 
2010; Rodriguez et al., 2007; Thai et al., 2007). The transcription factor c-Maf, a miR-
155 target, was up-regulated in mir-155 deficient CD4+ T cells resulting in enhanced Th2 
differentiation (Rodriguez et al., 2007). In addition, miR-155 in Treg cells promotes cell 
fitness by targeting suppressor of cytokine signaling (SOCS)1 (Lu et al., 2009). In terms 
of Th17 cell responses, miR-155 is necessary for the production of IL-17 and IFNγ 
during Helicobacter pylori infection (Oertli et al., 2011),	  as well as mouse models of 
inflammatory diseases such as experimental autoimmune encephalomyelitis (EAE) 
(Murugaiyan et al., 2011; O'Connell et al., 2010) and collagen induced arthritis (CIA) 
(Bluml et al., 2011). 
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 Other miRNA have also been implicated in T cell regulatory pathways. The miR-
29a/b and miR-17~92 clusters have also been shown to have a role in CD4+ Th cell 
development and function (Baumjohann and Ansel, 2013). The miR-29 family was 
shown to limit Th1 cell differentiation and IFNγ production by targeting mRNAs 
encoding T-bet, eomesodermin (Eomes), and IFNγ (Ma et al., 2011; Steiner et al., 2011). 
As such, miR-29 can suppress immune responses to intracellular pathogens by limiting 
pro-inflammatory IFNγ production (Ma et al., 2011). Moreover, it was demonstrated that 
the miR-17~92 cluster promotes T cell survival and proliferation by targeting Pten and 
Bim messages. Over expression of the miR-17~92 cluster in T cells results in 
lymphoproliferation and autoimmunity (Baumjohann and Ansel, 2013; Xiao et al., 2008).   
 In addition to miRNA, other ncRNA such as long non-coding RNA (lncRNA) are 
emerging as important players in controlling gene expression programs that are critical 
for lineage commitment and pluripotency (Guttman et al., 2009; Guttman et al., 2011). 
During T cell differentiation, a lncRNA NeST was found to enhance IFNγ expression by 
regulating the epigenetics of the IFNγ locus (Gomez et al., 2013). The enhanced 
production of IFNγ by NeST led to increased viral and bacterial susceptibility among 
transgenic animals (Gomez et al., 2013). Assessing the function of ncRNA during CD4+ 
Th cell differentiation is therefore necessary for a comprehensive understanding of T cell 
specification and gene regulation. For this reason, annotation and function of lncRNAs 
are emerging for CD4+ Th cell subsets (Hu et al., 2013). 
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Figure 4. miRNA biogenesis and role of small RNAs in T cell differentiation. (A) The 
miRNA gene is transcribed by RNA Polymerase II and processed by Drosha and DGCR8 
in the nucleus. This pri-miRNA is exported to the cytoplasm by Exportin 5, and then 
further processed by Dicer to a mature duplex. The guide strand of mature miRNA is 
incorporated into the miRISC complex where it is directed to its complementary targets, 
resulting in changes in gene expression. (B) Depiction of aberrant cell proliferation and 
differentiation upon stimulation of T cells lacking key molecules of the miRNA 
biogenesis pathway (Reprinted by permission from Macmillan Publishers Ltd: Nature 
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1.5 Objectives for thesis research and summary of findings 
 Due to the well-characterized nature of murine CD4+ Th cell differentiation, I 
chose to focus on the Th17 cell program for my graduate research to examine gene 
regulatory networks that incorporate miRNA. My research has identified both miR-29 
and miR-155 as important factors in regulating Th17 cell development and suppressing 
alternative Th cell fates. This research has also revealed the importance of chromatin 
regulators, specifically the Polycomb repressive complex 2 (PRC2) and Jarid2, in altering 
the chromatin state of Th17 cells and inhibiting lineage commitment. I further highlight 
the mechanism by which miR-155 promotes Th17 cytokine expression and identify small 
molecule inhibitors of miR-155 that have the ability to inhibit the production of Th17 
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2.1 Experimental animals 
Male and female BALB/c, STAT4 KO (Kaplan et al., 1996b), STAT6 KO 
(Kaplan et al., 1996a), and 2D2 (Bettelli et al., 2003) mice were purchased from The 
Jackson Laboratory. STAT4 KO and STAT6 KO mice were backcrossed onto the 
BALB/c background. miR-155 KO mice	  (Thai	  et	  al.,	  2007)	  were purchased from The 
Jackson Laboratory and backcrossed up to 12 generations onto the C57BL/6 background 
(Taconic). B6.SJL (CD45.1) and Rag2-/- mice were purchased from Taconic. STAT3fl/fl; 
CD4-cre on a C57BL/6 background and littermate controls were provided by Charles 
Egwuagu’s laboratory (National Eye Institute, NIH, USA). The the knock-out first 
conditional strategy was utilized to create a Jarid 2 floxed allele. Briefly the 
Jarid2tm1a(KOMP)Wtsi allele on a C57BL/6 background obtained from the International 
Knockout Mouse Consortium was bred to Flp transgenic mice from The Jackson 
Laboratory  to genetrate  a conditional allele (Jarid2fl/+) (Rodriguez et al., 2000). In this 
conditional allele, exon 3 is flanked by loxP sites in a strategy that is essentially identical 
to a previously published conditional allele of Jarid2 (Mysliwiec et al., 2006). The 
Jarid2fl/+ mice were bred to CD4-cre transgenic mice purchased from Taconic (Lee et al., 
2001) to generate CD4+ Jarid2 ff mice which delete Jarid2 in T cells at the double 
positive stage; all mature T cells in these mice are Jarid 2 deficient.  
Primers for CD4-cre genotyping were Forward 5’ CCCAACCAACAAGAGCTC 
3’ and Reverse 5’ CCCAGAAATGCCAGATTACG. Jarid2 genotyping primers for the 
floxed allele were Forward 5’ TAGTCAGGGCAAGGTGGAAG 3’ and Reverse 5’ 
TCCCAACCTTCCTAATGCT 3’.  
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For bone marrow reconstitution, B6.SJL (CD45.1) recipient mice were 
conditioned with 900 Rads via a Cs137 source prior to injection of 3 million donor bone 
marrow cells. Mice were administered Trimethoprim/Sulfamethoxazole (TMS) 
antibiotics via drinking water for 5 weeks. All animal experiments were done in 
compliance with the guidelines of the NIH/NIAID Institutional Animal Care and Use 
Committee.  
2.2 Parasites and infection 
T. gondii cysts from the Type II avirulent strain ME-49 were prepared from the 
brains of infected C57BL/6 mice. For experimental infections, mice were inoculated by 
oral gavage with 0.5 mL of PBS for an average of 50 T. gondii cysts per animal (Wilson 
et al., 2010).  
2.3 Isolation of small intestine lamina propia 
Single-cell suspensions were prepared from spleen, pooled peripheral lymph 
node, and mesenteric lymph node by mechanical disruption and passage through 40 µm 
cell strainers (BD Biosciences). For isolation of lamina propria lymphocytes, the small 
intestine was collected in ice-cold HBSS buffered in 25 mM HEPES with 5% FBS. After 
careful removal of fatty tissue and fecal contents, the intestine was opened longitudinally 
and cut into small pieces. The intestinal fragments were washed once with HBSS 
containing 2 mM EDTA and 25 mM HEPES followed by an incubation step at 37°C with 
shaking in HBSS containing 10% FBS, 5 mM EDTA, 15 mM HEPES, and 0.015% DTT. 
The intestinal fragments were washed 5 times with HBSS containing 25 mM HEPES and 
5% FBS and digested with Liberase TL (0.17 mg/ml) and DNAse (30 µg/ml) in pre-
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warmed Iscove’s Complete Media containing 5% FBS and then incubated for 30-60 
minutes at 37°C with shaking. Digested intestinal fragments were washed with HBSS 
containing 25 mM HEPES and 5% FBS followed by passing tissue through a 70 µm and 
40 µm strainer (BD Biosciences) to obtain single cell suspensions for downstream 
analysis. 
2.4 Polarization and activation of mouse T cells 
Splenic and lymph node T cells were obtained by disrupting organs of 6-9 week-
old mice. Single-cell suspensions were prepared from spleen, pooled peripheral lymph 
node and mesenteric lymph node by mechanical disruption and passage through 40 µm 
cell strainers (BD Biosciences). Naïve T cells were obtained either by sorting using a BD 
FACS Aria cell sorter to identify CD4+CD44-CD62LhighCD25low cells or were positively 
selected for CD4+ cells using a Miltenyi Biotec AutoMACS. Cells were cultured on 
plate-bound anti-CD3 (1 µg/mL) (clone 145-2C11) and anti-CD28 (1µg/ml) (clone 
37.51) for 4 days with various combinations of antibodies and cytokines: for Th1 
conditions, 10 ng/mL of IL-12 and 10 µg/mL of anti-IL-4 (clone 11B11); for Th2 
conditions, 10 ng/mL of IL-4, 10 ng/mL of IL-2, 10 µg/mL anti-IL-12 (clone C17.8) and 
anti-IFNγ (clone XMG1.2); for Th17 conditions, 10 ng/mL of IL-6 and 0.5 ng/mL of 
TGFβ, with 10 µg/mL of anti-IL-4, anti- IL-12 and anti-IFNγ and when indicated 10 
ng/mL of IL-1β was also added; for iTregs, 50 U/mL of IL-2, 10 µg/mL of TGFβ with 10 
µg/ml of anti-IL-4, anti- IL-12 and anti-IFNγ; for Th0 conditions, 50 U/mL of IL-2 with 
10 µg/ml of anti-IL-4, anti- IL-12 and anti-IFNγ. Cells were cultured in 24 well plates for 
3 days and then expanded in the presence of 50 U/mL IL-2 in 12 well plates for 1 or 2 
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days, except for Th17 cells that were expanded in the presence of all cytokines and 
antibodies. For murine studies, all recombinant cytokines were purchased from R&D and 
blocking antibodies and crosslinking antibodies were custom made from hybridomas 
(Harlan). 
2.5 Polarization and activation of human T cells  
Human peripheral blood mononuclear cells (PBMCs) were prepared from 20-60 
year-old healthy donors by the Department of Transfusion Medicine at NIH. The 
acquisition of blood products was approved according to the Institutional Review Board 
and in accordance with the Declaration of Helsinki. Naïve CD4+ T cells were sorted 
using the markers of CD4+CD25-CD45RA+. For Th cell subset skewing, 24-well plates 
were coated overnight at 4°C or 4 hours at 37°C with 2 µg/mL in PBS containing anti-
CD3 (clone UCHT1) and anti-CD28 (clone CD28.2). The cells were cultured with 10% 
FBS IMDM (GIBCO) for 5-6 days along with the respective cytokine cocktail. If 
necessary, cells were split after 3 days with a similar cocktail of antibodies. For Th1 
conditions, 1 ng/mL of IL-12, 50 U/mL of IL-2 with 1 µg/mL of anti-IL-4; for Th2 
conditions, 20 ng/mL of IL-4, 50 U/ml of IL-2 with 1 µg/mL of anti-IL-12 and anti-IFNγ; 
for iTreg conditions, 50 U/mL of IL-2, 10 µg/mL of TGFβ with 1 µg/mL of anti-IL-4 and 
anti-IFNγ; for Th17 conditions, 50 U/mL of IL-2, 10 ng/mL of each IL-1β, IL-6, and IL-
23 and 10 ng/mL of TGFβ with 1µg/mL of anti-IL-4 and anti-IFNγ. For human cultures, 
all recombinant cytokines were purchased from Peprotech and blocking antibodies for 
IL-12, IL-4, and IFNγ were affinity-purified polyclonal goat IgG from R&D Systems. 
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2.6 Retroviral cloning and T cell transduction 
Mouse Atf3 was PCR amplified from cDNA clones obtained from Origene 
(MC201919) and subcloned into the MSCV-IRES-GFP vector provided by Ken Murphy 
(Washington University). Mouse miR-29a was first amplified from the mouse genome 
and then cloned into a MDH1-PGK-GFP based vector. Plasmid insertion was verified by 
sequencing and retroviral supernatants were generated. Transductions of CD4+ T cells 
was achieved by first polarizing mouse T cells towards Th17 cell differentiation 
(described above) for one day. The following day, Th17 cell cultures were transduced by 
spin-infection at 700 x g at 32°C for 90 minutes in the presence of retroviral supernatant 
and 5 µg/mL polybrene (Sigma-Aldrich). Cells were returned to the incubator for another 
6 hours and then viral media was replaced with fresh media. Th17 polarization was 
continued for 3 days followed by re-stimulation with PMA and Ionomycin in the 
presence of Golgi block for 4 hours. Transduced Th17 cell cultures were then fixed with 
1% paraformaldehyde (Electron Microscopy Sciences) followed by intracellular cytokine 
staining in 1x PBS with 0.1% TritonX100 (Sigma-Aldrich).  
2.7 Flow cytometry of intracellular cytokines 
Mouse or human polarized T cells were stimulated with 20 ng/mL of phorbol 12-
myristate 13-acetate (PMA) and 1 µg/mL of ionomycin in the presence of BD Golgi Plug 
(BD Bioscience) containing brefeldin A for 4 h at 37°C. Cells were subsequently stained 
with fixable viability dye (eBioscience) and then permeabilized in 500 µL of eBioscience 
Perm-Fix solution overnight at 4°C. Cells were washed with PBS and stained with anti- 
CD4, CD44, TCRβ, CD45.2, CD45.1, Vβ11, IL-17A, IL-22, IFNγ, IL-4, Foxp3, RORγt, 
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BATF, and IRF4 antibodies (eBioscience) for 1 h at 4°C. After washing, stained cells 
were assayed with a BD LSRII flow cytometer and the results analyzed using FlowJo 
software. 
2.8 Passive Experimental Autoimmune Encephalomyelitis (EAE) and mean clinical 
score 
Sorted naïve CD4+Vβ11+CD44- T cells from TCR(2D2) mice were activated with 
plate-bound anti-CD3 and anti-CD28 (10 µg/mL) in serum-free media under 
Th17(TGFβ) or Th17(23) conditions. After one day of polarization, T cells were 
transduced with miR-29a GFP-rv or vector control GFP-rv. Following transduction and 5 
days of Th17 polarization, activated T cells were sorted based on GFP and 0.5 million 
cells were adoptively transferred into female Rag2-/- mice. Mice were scored according 
to the following criteria: 0, no disease; 1, decreased tail tone; 2, hind-limb paralysis; 3, 
complete hind-limb paralysis; 4, both hind- and front-limb paralysis; 5, moribund state. 
2.9 Induction of Experimental Autoimmune Uveitis (EAU) by active immunization 
Mice were immunized with 150 µg interphotoreceptor retinoid-binding protein 
(IRBP) and 300 µg of human IRBP peptide (1–20) in a 0.2 mL emulsion 1:1 vol/vol with 
Complete Freund's adjuvant (CFA) containing Mycobacterium tuberculosis strain 
H37RA (2.5 mg/mL). The mice also received Bordetella pertussis toxin (0.2 µg/mouse) 
concurrent with immunization, and clinical disease was established by funduscopy. Eyes 
were harvested for histologic or funduscopic evaluation at  0, 7, 10, 14, or 21 days after 
immunization. For histology, eyes were harvested, fixed in 4% glutaraldehyde for 30 
minutes, and then transferred to 10% buffered formalin. After adequate fixation, 
	   24	  
specimens were dehydrated through graded alcohols and embedded in methacrylate. 
Serial vertical sections through the papillary–optic nerve plane were cut and stained with 
hematoxylin and eosin. Photographs of representative sections were taken on a 
photomicroscope (Carl Zeiss AG, Oberkochen, Germany). Clinical disease was 
established and scored by funduscopy (Oh et al., 2011; Yu et al., 2011). Briefly, 
following intraperitoneal (IP) injection of ketamine (1.4 mg/mouse) and xylazine (0.12 
mg/mouse), pupils were dilated by topical administration of 1% tropicamide ophthalmic 
solution (Alcon, Inc., Fort Worth, TX). To avoid a subjective bias, evaluation of the 
fundus photographs was conducted without knowledge of the mouse identity by a masked 
observer. At least six images (2 posterior central retinal views, 4 peripheral retinal views) 
were taken from each eye by positioning the endoscope and viewing from superior, 
inferior, lateral, and medial fields. Each individual lesion was identified, mapped, and 
recorded. The clinical grading system for retinal inflammation was used as established 
previously (Xu et al., 2008). 
2.10 RNA Purification and quantitative PCR 
Total RNA was isolated using a mirVana (Applied Biosystems) isolation kit. 
cDNA was prepared using TaqMan Reverse Transcription Reagents (Applied 
Biosystems) with random hexamers for primer/probe sets IL-22, IL-17A, IL-17F, IL-10, 
IL-9, ATF3, JARID2, IFNγ, Eomes, Tbet, IRF4, RORC, and BATF. For microRNA 
expression, cDNA was prepared using TaqMan microRNA reverse transcription kit 
(Applied Biosystems) with primer/probe sets for miR-155, miR-29a, miR-29b, and U6.  
Quantitative PCR was performed on a 7900HT Fast Real Time PCR Systems (Applied 
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Biosystems). CT values from triplicate samples were averaged and relative expression 
was calculated using the 2-ΔΔCT method. 
2.11 miRNA expression profiling 
Total RNA was extracted from cell cultures on day 4. RNA concentration was 
determined using the Qubit RNA broad range assay in the Qubit Fluorometer 
(Invitrogen). A Eukaryote Total RNA Nano Series II chip on a 2100 Bioanalyzer 
(Agilent) was used to confirm the concentration and determine the integrity of the RNA. 
One hundred ng of total RNA was used as the starting material for miRNA profiling 
using the nCounter Mouse miRNA Expression Assay Platform (NanoString 
Technologies). Sample preparation and flow-cell hybridization was performed per 
manufacturer’s instructions at the DNA Sequencing and Digital Expression Core Facility 
(National Cancer Institute). Per manufacturer’s instructions, data were normalized to the 
sum of positive control count values provided in assay to account for lane to lane 
variation. Background determination was set by the mean +2x standard deviation of the 8 
negative control detectors. Expression counts were normalized to the mean signal level of 
a number of housekeeping genes (Actb, B2m, Gapdh, Rpl19, Rplp0). 
2.12 Protein quantitation  
Cell lysates were prepared by lysis in 420 mM NETN buffer containing protease 
inhibitor and western blot analysis was performed using standard methods. Image J 
(http://imagej.nih.gov/ij/) was used to quantify protein expression levels from digital 
images of western blots and each assay was normalized to α-tubulin loading controls. The 
concentration of IL-22, IL-9, and IL-10 in the supernatant of Th17 cell cultures was 
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measured using the corresponding Mouse ELISA Ready-Set-Go! Kit (eBioscience) 
following the manufacturer’s instructions. 
2.13 Chromatin Immunoprecipitation (ChIP), ChIP-seq and ChIP-exo 
Polarized Th17 cells on day 4 were cross-linked with 2% paraformaldehyde at 
room temperature for 5 minutes followed by quenching with 125 mM glycine. The cells 
were then harvested and washed with cold phosphate-buffered saline. After obtaining a 
cell pellet for 10 million cells, these cells were lysed in RIPA buffer containing 
proteinase inhibitors. Chromatin was sheared into fragments of 200 base pairs in length 
by sonication of the cell lysate with a Diagenode Bioruptor (ten pulses of 30s, followed 
by eight pulses of 15s). After spinning down the cell debris, the sheared chromatin was 
added to the respective antibody immobilized on Protein A magnetic beads (Invitrogen), 
followed by overnight incubation at 4°C with rotation. Protein-DNA complexes were 
washed in low-salt, high-salt RIPA buffer, LiCl and Tris-EDTA buffers. Protein-DNA 
complexes were treated with 0.3% SDS, 1 mg/mL proteinase K (Invitrogen) and 
incubated overnight at 65°C to reverse crosslinking. The eluted DNA was purified by 
phenol-chloroform extraction and ethanol precipitation and suspended in 40 µL of Tris-
EDTA. Real-time PCR was performed to quantify the ChIP assay and the amount of the 
immunoprecipitated DNA samples was normalized against input DNA samples. 
Antibodies include H3K4me3 (ab8580, Abcam), H3K27me3 (07-449, Millipore), Jarid2 
(ab48137, Abcam), Suz12 (D39F6, Cell Signaling), c-Maf (M-153, Santa Cruz), Pol II 
(4H8, Abcam), and STAT3 and IgG control from Cell Signaling. For STAT3 ChIPs, 
Th17 polarized cells were stimulated for 60 min with recombinant IL-6 (25 ng/mL) to 
allow STAT3 translocation to the nucleus. For ChIP-exo, chromatin was sheared to 200 
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base pairs and frozen chromatin was provided to Peconic LLC (State College, PA) along 
with antibodies.  
2.14 High throughput RNA sequencing procedure  
Total RNA was extracted from activated miR-155 KO, STAT3KO, STAT4KO, 
STAT6KO and WT CD4+ T cells cultured under Th1, Th2 or Th17 polarizing conditions 
for 4-5 days. RNA concentration was determined using the Qubit RNA broad range assay 
in the Qubit Fluorometer (Invitrogen) and RNA integrity was determined using 
Eukaryote Total RNA Nano Series II ChIP on a 2100 Bioanalyzer (Agilent). Three 
independent biological replicates were pooled for RNA-seq. RNA-seq libraries were 
prepared from 1 µg of total RNA using the TruSeq RNA sample prep kit following 
manufacturer’s instructions (Illumina). Briefly, oligo-dT purified mRNA was fragmented 
and subjected to first and second strand cDNA synthesis. cDNA fragments were blunt-
ended, ligated to Illumina adaptors, and PCR amplified to enrich for the fragments ligated 
to adaptors. The resulting cDNA libraries were verified and quantified on Agilent 
Bioanalyzer, and single-end 96 cycle RNA-seq was conducted using the GAIIx Genome 
Analyzer (Illumina) for miR-155 KO and WT Th17 cells and 50 cycle paired-end RNA-
seq was conducted for STAT4 KO and STAT6 KO Th1 and Th2 cells, respectively. 
2.15 RNA-seq analysis 
For RNA-seq analysis, reads from single or paired-end RNA-seq were mapped to 
the mouse genome (NCBI 37, mm9) using the splice-aware aligner TopHat (version-
1.3.1) (Trapnell et al., 2009) with option --mate-inner-dist 160 --coverage-search --
microexon-search --max-multihits 20.  In short, using a two-step mapping processes, 
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TopHat first calls Bowtie (version-0.12.7) (Langmead et al., 2009) to align reads that are 
directly mapped to the reference genome (with no gaps). Bowtie then determines the 
possible location of gaps in the alignment based on canonical and non-canonical splice 
sites flanking the aligned reads. Finally, Bowtie uses gapped alignments to align the reads 
that were not aligned in the first step. Aligned reads were then visualized on a local 
mirror of the UCSC Genome Browser (Kent et al., 2002).   
For differentially expressed gene and miRNA signature analyses, gene expression 
quantification was performed by counting aligned reads on each gene for each condition 
using in-house codes. DEGseq (Wang et al., 2010) was then applied to identify 
differentially expressed genes between two conditions with addition options p value 
threshold 1e-5 and fold change threshold 1.4. To identify putative target genes, a ranked 
gene list from up-regulated to down-regulated based on the log2 of the ratio of the 
expression level of each gene in the two conditions was supplied to Sylamer (van Dongen 
et al., 2008) to statistically calculate the enrichment of seed sequences of all known 
miRNAs (version 15 from miRbase.org).  A list of 220 putative target genes was 
identified by choosing up-regulated genes containing miR-155 seed sequences 
(AGCATTA and GCATTAA) that pass the E-value threshold (Bonferroni-corrected) of p 
value < 0.01. Comparison of this putative target gene list against 134 and 256 putative 
miR-155 target mRNAs phylogenetically predicted by PicTar (http://pictar.mdc-
berlin.de/) (Krek et al., 2005) and TargetScan (http://www.targetscan.org/)(Lewis et al., 
2003) gave 15 putative miR-155 target mRNAs in common among the three methods. 
The False Discovery Rate (FDR) of the overlapped genes was then estimated by shuffling 
the RefSeq gene list 1000 times, randomly picking up 134 and 256 genes and getting the 
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average number of genes that overlap with the Sylamer miR-155 target gene list, which 
are 1.4 and 2.5, respectively. The FDR for the overlapped genes (1.4 out of 25 and 2.5 
out of 42 genes) is about 6% for both comparisons. 
2.16 ChIP-seq and ChIP-exo analysis 
Reads from ChIP-seq were mapped to the mouse genome (NCBI 37, mm9) using 
the short read, memory efficient aligner Bowtie (version-0.12.7) (Langmead et al., 2009) 
with option -p 8 --chunkmbs 256 -a --best --strata -m 20. Unique reads were considered 
by instructing Bowtie to refrain from reporting any alignments for reads that have more 
than 20 reportable alignments. Reads from ChIP-exo were mapped by Peconic (State 
College, PA) to the mouse genome (NCBI 37, mm9) using BWA (version 0.5.9) with 
default options allowing one gap open and a maximum number of three alignments for 
any read that aligned across the genome. Sub-module of SICER (version-1.1) (Zang et 
al., 2009) was used on BED files containing the unique reads to determine window size 
(Abraham et al., 2013) for Jarid2, Suz12 and H3K27me3. The window sizes for each 
ChIP-seq were as follows: 2102 bp for Jarid2, 397 bp for Suz12 and 2852 bp for 
H3K27me3. SICER-df.sh was used for Suz12, Jarid2 and H3K27me3 analysis with a gap 
size of 0 for Jarid2, Suz12 and H3K27me3. All SICER-df.sh analysis had an FDR cutoff 
of 0.01. For ChIP-exo analysis, SICER-rb.sh was used to find enriched Jarid2 and Suz12 
islands with an E value cut-off of 0.1, a window size of 50 and a gap size of 100. For c-
Maf analysis, MACS (Version 1.4.2) was used for c-Maf binding enrichment using the 
following parameters "–f BED –g mm –p 1E-5 –w –S" using the duplicates processed 
BED files of c-Maf-miR-155-WT against c-Maf-miR155-WT-Input and c-Maf-miR-155-
KO against c-Maf-miR155-KO-Input. For comparison of c-Maf miR-155 KO vs WT, 
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MACS2 (Version-2.0.9) was used with the following parameters "–f BED –g mm –p 1E-
5 –B" against the duplicates processed BED files. The output from MACS2.0 was used 
with a sub-module of MACS2 "bdgdiff" tool that identifies differential binding regions, 
with a minimum peak length of 200, differential peak consideration cutoff of 5 and a gap 
size between any two peaks to be 30. 
For visualization of RNA-seq and ChIP-seq tracks, wiggle files were generated 
from BAM files using custom Python scripts and then provided to D-Peaks (Brohee and 
Bontempi, 2012) to plot the coverage tracks (tags per million) at specified locations on 
the genome. 
The Th17 cell specification regulatory network (KCRI) (Ciofani et al., 2012) was 
downloaded from http://th17.bio.nyu.edu/pages/cytoscape.html. Targets of miR-155 and 
Jarid2-PRC2 were integrated into the KCRI network to generate an updated Th17 cell 
regulatory network. Associations between transcription factors and miR-155 were added 
based on available ChIP-seq evidence. Network data integration, visualization and 
analysis were performed using the Cytoscape platform (Smoot et al., 2011). 
2.17 Statistics 
GraphPad Prism 5.0 was used for statistical analysis (unpaired, two-tailed, t test 
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3. Regulation of non-coding RNA by Signal Transducer and Activator 
of Transcription (STAT)s in CD4+ Th differentiation 
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3.1 STATs regulate Th1, Th2 and Th17 cell differentiation 
	   Naïve CD4+ T cells differentiate into distinct Th cell populations and subsequently 
produce signature cytokines based on the variety of pathogens they encounter. The 
identification of distinct factors and in vitro culture conditions that can polarize CD4+ T 
cells into the unique lineages has enabled mechanistic insight into the various signaling 
pathways and gene expression profiles that are associated with each of the subsets. It 
became apparent that activation of the STAT family of transcription factors is critical for 
proper CD4+ Th cell differentiation (O'Shea and Paul, 2010). The phosphorylation of 
STATs by Janus kinases (JAK-STAT signaling pathway) results in STAT dimerization 
and translocation to the nucleus. In the nucleus, STATs bind to a recognition sequence 
(TTCCC) where they can either promote or suppress transcription of neighboring genes 
(Stark and Darnell, 2012). 
 The activation of STATs and expression of key transcriptional regulators form a 
complex network involving positive regulation of a lineage differentiation while 
suppressing alternative fates. Among the seven STAT family members, STAT4 in 
conjunction with STAT1 plays a pivotal role in Th1 cell differentiation by enhancing Th1 
master regulator Tbet expression leading to the production of IFNγ (Mullen et al., 2001). 
In Th2 cells, IL-4 activates STAT6 resulting in the transcription of Gata3 and in turn 
augmenting IL-4 production (Takeda et al., 1996). STAT3 and STAT5 are key players in 
Th17 and Treg cell differentiation, respectively. In Th17 cells, IL-6 signaling activates 
STAT3 to induce RORγt expression (Yang et al., 2011), whereas IL-2 allows STAT5 to 
induce Foxp3 expression in Treg cells (Burchill et al., 2007). Although the role of STATs 
in CD4+ Th cell differentiation has been extensively studied, STAT regulation of 
ncRNAs in the context of the immune system is less well understood. We explored the 
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role of STATs in modulating the expression profile of regulatory non-coding RNAs in 
the CD4+ Th cell subsets.  
As an overview, we initially performed miRNA expression profiling on CD4+ T 
cells from mice with specific STAT-deficiencies and littermate controls during in vitro 
polarization to different Th cell subsets (Th1, Th2, and Th17). From this profile, we 
discovered numerous differentially expressed miRNA that are putatively regulated by 
different STAT family members (STAT4, STAT6 and STAT3). As a result, we 
hypothesized that the expression of certain miRNAs among the different CD4+ Th cell 
subsets are induced by STAT4 in Th1, STAT6 in Th2 and STAT3 in Th17 cells. To 
address whether STATs directly upregulate miRNA, we took advantage of publicly 
available genome-wide binding profiles for STAT3 (Durant et al., 2010). We found that 
STAT3 binds to miRNA genes that are highly expressed in Th17 cells. Herein we 
describe our analyses of the miRNA profiling and published ChIP-seq datasets. We 
further reveal a STAT3-miR-155 and STAT3-miR-29a axis and investigate the putative 
role of STAT3 in inducing miRNA-29 expression in Th17 cells.  
3.2 Altered CD4+ T helper cell miRNA expression in the absence of STAT4, STAT6 
and STAT3 
 To assess whether STATs regulate miRNA expression in CD4+ T cells, we 
differentiated CD4+ T cells from STAT4 KO, STAT6 KO and STAT3fl/fl; CD4-cre mice 
along with littermate controls into Th1, Th2, and Th17 cells, respectively. We performed 
miRNA expression profiling on these cells using the NanoString platform. Following 
normalization, we plotted the miRNA counts in a scatter plot and highlighted miRNA 
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with at least a 1.5 fold difference between STAT-deficient and littermate control mice 
(Figure 5A-C). Based on this profile, we observed unique STAT-dependent miRNA 
signatures among the different CD4+ Th cell lineages. For example, miR-21, miR-155 
and the miR-29a/b cluster were highly expressed in the Th17 cells, and these miRNAs 
required STAT3 expression (Figure 5C-D). Using RT-qPCR, we were able to further 
validate the differential expression of miR-132 in Th1 cells; miR-132, miR-101 and miR-
21 in Th2 cells; miR-155, miR-21, miR-29 cluster, and miR-182 cluster in Th17 cells 
(Figure 5E-G). These validations revealed statistically significant miRNA differential 
expression between the relevant STATs in each of the CD4+ Th cell subsets. 
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Figure 5. STATs are required for miRNA expression in CD4+ Th cell subsets. 
Analysis of absolute miRNA read counts obtained from Th1 cells (A), Th2 cells (B) and 
Th17 cells (C) in the presence and absence of their relevant STATs. miRNA with >1.5 
fold change are highlighted in red and raw digital reads were first normalized to the sum 
of  positive control count values per manufacturer’s recommendation and to 
housekeeping genes. (D) Depiction of absolute expression for representative miRNA 
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from Th17 cells that require STAT3 for expression and miR-15b as a control. (E-F) 
Taqman validations from differentially expressed miRNA found in (A), (B) and (C) and 
normalized to U6 and to their littermate controls. CD4+ T cells were obtained from lymph 
nodes of STAT4 KO, STAT6 KO and STAT3 KO and littermate controls (wild type) and 
were polarized under Th1 cell, Th2 cell and Th17 cell conditions for 4 days prior to 
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3.3 The Th17 cell transcriptional program targets miRNA and STAT3 promotes the 
in vivo expression of miR-155   
 Since miR-155 and miR-29a/b are highly expressed in Th17 cells and require 
STAT3 for their expression, we investigated whether the Th17 cell transcriptional 
components (Figure 3) directly bind to these miRNA genes. Analysis of the Mir29 and 
Mir155 loci revealed highly enriched H3K4me3 and P300 sites, which suggests an active 
transcriptional region in Th17 cells (Figure 6A-B). Furthermore, through ChIP-seq 
analysis we established that STAT3, IRF4 and BATF, but not RORγt bind to Mir29 and 
Mir155 (Figure 6A-B).  Of note, a similarly active transcriptional pattern was found for 
Rorc, the gene encoding the Th17 cell “master” regulator RORγt (Figure 6C). To validate 
the enrichment of STAT3 binding in the vicinity of these miRNA, we performed STAT3 
ChIP on Mir29ab and Mir155 loci (Figure 6D). We found increased occupation of 
STAT3 at the highly expressed miRNA loci compared to a 5kb distant region from the 
miR-155 promoter as a negative control (Figure 6D). 
 To determine whether CD4+ T cell expression of STAT3 is necessary for the 
upregulation of miR-155 in vivo, we set up a collaboration with the laboratory of Dr. 
Charles Egwuagu in the National Eye Institute (NIH). We chose Experimental 
Autoimmune Uveitis (EAU) as an experimental model, as this eye disorder involves T 
cell specific expression of STAT3 for disease development (Figure 7A), as well as results 
in a Th17 cell-rich environment that requires STAT3 (Figure 7B). In comparison to 
littermate controls (wild type), CD4-STAT3 KO mice did not induce miR-155 expression 
during EAU (Figure 7C), which can implicate miR-155 in disease progression (Escobar 
et al., 2013). 
	   38	  
 
 
Figure 6. The Th17 cell transcriptional network targets miRNA genes. (A-C) 
Genome browser screen-shot of mouse Mir29ab (A), Bic/Mir155 (B) and Rorc (C) loci 
depicting H3K4me3, P300, STAT3, IRF4, BATF, and RORγt ChIP-seq of Th17 cell 
cultures. Data were downloaded from GSE40918 (Ciofani et al., 2012). Arrows depict 
regions used for validation. (B) STAT3 or IgG ChIP-qPCR for Mir29ab, Mir155 and a 
negative control (5kb distant region from the miR-155 promoter). ChIPs were normalized 
to input and statistical significance was determined using Student’s t test (* p < 0.05, ** p 
< 0.01, ns = not significant). 
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Figure 7. Resistance of CD4-STAT3 KO mice to EAU correlates with defective 
expression of miR-155. (A) Wild type or CD4-STAT3 KO mice were immunized with 
IRBP in CFA, and 21 days after immunization the eyes were examined by funduscopy. 
(B) Freshly isolated lymph node cells from wild type or CD4-STAT3 KO mice (day 21 
after immunization) were analyzed for intracellular cytokine staining. CD4+ T cells were 
gated on and the numbers in each quadrant indicate the percentage of CD4 or IL-17A 
expression. (C) Lymph node cells were isolated at Day 14 and Day21 time points after 
immunization from mice described, and RNA was analyzed for the expression of miR-
155 by RT-qPCR. Data are representative of at least 2 independent batches of 
experiments (n = 4 or 5 mice per experiment). Statistical significance was determined 
using Student’s t-test (***p < 0.001 and ****p < 0.0001) (Reprinted by permission from 
Association for Research in Vision and Ophthalmology, Escobar et al., 2013). 
during EAU. In addition, the contribution of miR-155 in the
susceptibility to EAU appears to be CD4! T-cell intrinsic.
However, miR-155 may have wide ranging effects in the
immune system and we do not yet have a complete
understanding of its functions. On the one hand, it is essential
for Treg function, but it also is crucial for effector T-cell
function. The ability to delete miR-155 conditionally in specific
cell types would demonstrate its contribution in various
immune responses. In addition, systematic identification of
miR-155 targets in individual cell types is key toward
understanding its mechanisms of action, particularly since its
targets may vary depending on the cell type.
FIGURE 5. Preferential miR-155 expression in Th17 cells is activated by STAT3. (A) Relative abundance of mature miR-155-5p and -3p, guide, and
passenger strand respectively, among T-cell subsets were obtained from http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc"GSE21630. (B) STAT3
ChIP-seq analysis in Th17 cells using data from http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc"GSM652877. (C) STAT3 ChIP-qPCR in Th17
cells using anti-STAT3 or nonspecific IgG control and primers that span the peak in (B). (D) Näıve CD4! T cells from WT or CD4-STAT3KO mice
were stimulated with anti-CD3/anti-CD28 antibodies for 4 days in medium containing IL-1b (10 ng/mL), IL-6 (10 ng/mL), or both cytokines, and miR-
155 expression was examined using RT-qPCR. (E) Näıve CD4! from WT and CD4-STAT3KO mice were stimulated under Th17 or Th2 polarization
condition for 4 days, and miR-155 expression was assayed using RT-qPCR. Data represent at least 3 independent experiments. Statistical significance
was determined using Student’s t-test (**P < 0.01, ***P < 0.001, ****P < 0.0001).
FIGURE 6. Resistance of CD4-STAT3KO mice to EAU correlates with defective expression of miR-155. (A) WT or CD4-STAT3KO mice were
immunized with IRBP in CFA and 21 days after immunization eyes were examined by funduscopy. (B) Freshly isolated LN cells from WT or CD4-
STAT3KO mice (day 21 after immunization) were analyzed by the intracellular cytokine staining. CD4! T cells were gated and numbers in quadrants
indicate percentage of CD4! or IL-17A! T cells. (C) LN cells were isolated at 2 time points after immunization from mice described and their RNA
was analyzed for the expression of miR-155 by RT-qPCR. Data represent at least 2 independent batches of experiments (n " 5 per experiment).
Statistical significance was determined using Student’s t-test (***P < 0.001 and ****P < 0.0001).
STAT3/miR-155 Axis Promotes Th17 Development and EAU IOVS j June 2013 j Vol. 54 j No. 6 j 4023
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3.4 A role for STAT3 and miR-29a/b expression in CD4+ Th cell differentiation 
 MiR-29 was recently identified to regulate IFNγ and its Th1 associated genes, Tbet 
and Eomes (Ma et al., 2011; Steiner et al., 2011). In our miRNA profiling experiments, 
we found high miR-29a/b expression in Th17 cells (Figure 5C), which required STAT3 
for expression (Figure 5C-D and 5G). Since the miR-29a/b cluster is also a direct STAT3 
target (Figure 6A and D), we investigated the role of miR-29 in Th17 cells. Analysis of 
Th17 cells from STAT3 KO mice revealed a lack of IL-17a expression and high IFNγ 
expression (Figure 8A). Based on these findings, we hypothesized that this increased 
production of IFNγ in absence of STAT3 is due to the inability to upregulate miR-29a/b 
expression, which prevents IFNγ production by downregulating Tbet and Eomes. We 
validated the increased expression of miR-29 targets Tbet and Eomes along with IFNγ 
transcript levels in STAT3 KO Th17 cells when compared to WT littermates (Figure 8B). 
 We next investigated the expression profile of miR-29a/b among the different 
polarized CD4+ Th cell lineages (Th1 cells, Th2 cells, Th17 cells, and Treg cells). We 
found highest miR-29a expression in Th17 cells and iTreg cells (Figure 8C). Since 
STAT3 was necessary for the expression of miR-29 in Th17 cells, we examined whether 
STAT3 similarly drives miR-29a/b expression in iTreg cells. When CD4+ T cells were 
differentiated into iTreg cells in the presence or absence of STAT3, we observed a 
decrease in miR-29a/b expression in absence of STAT3 as compared to littermate 
controls (Figure 8D). The STAT3 KO iTreg cells also had a 5% increase in IFNγ (Figure 
8E) as well as an increase in Tbet and Eomes expression in comparison to littermate 
controls (wild type) (Figure 8F). 
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Figure 8. miR-29 downregulation correlates with increased IFNγ expression in 
STAT3 KO CD4+ Th cells. (A) Phenotypic analysis of Th17 cells from STAT3 KO and 
littermate control mice depicting IL-17a and IFNγ expression by flow cytometry. (B) 
Relative mRNA expression of IFNγ, Tbet and Eomes determined by RT-qPCR in Th17 
cells from STAT3 KO and littermate control mice. (C) RT-qPCR of miR-29a expression 
in CD4+ T cells cultured under Th0, Th1, Th2, Th17, and iTreg cell conditions for 4 days. 
(D) miR-29a/b expression in iTreg cells from STAT3 KO and littermate control (wild 
type) mice. (E) Phenotypic analysis of iTreg cells from STAT3 KO and littermate control 
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mice depicting Foxp3 and IFNγ expression by flow cytometry. (F) Expression of Tbet 
and Eomes in iTreg cells from STAT3 KO and littermate control mice. Relative gene 
expression was determined by normalizing to Gapdh and relative miRNA expression was 
found by normalizing to U6 and to naïve miR-29a expression. For all panels, the data are 
representative of two independent experiments using two mice per experiment. Error bars 
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3.5 A STAT3-miR-29 axis in Th17 (TGFβ) and Th17 (IL-23) cells  
IFNγ production by Th17 and iTreg cells has been described in multiple systems, 
mostly in vivo, as IL-17a+IFNγ+ and iTreg+IFNγ+ are associated with increased 
autoimmunity (Hirota et al., 2011). The adoptive transfer of in vitro derived Th17 cells 
has recently been shown to lead to the induction of Experimental Autoimmune 
Encephalitis (EAE) in mice. Following adoptive transfer, these pathogenic Th17 cells 
begin to produce high levels of IFNγ and express Tbet and Eomes (Ghoreschi et al., 
2010). Interestingly, the differentiation requirements for these pathogenic Th17 cells do 
not involve TGFβ signals that are conventionally associated with Th17 cell polarization, 
but rather require IL-23 signaling. These cells were subsequently named Th17 (23) cells 
since they require IL-23 to delineate from the conventional in vitro polarization of Th17 
cells that need TGFβ, Th17 (TGFβ) (Ghoreschi et al., 2010).  
 To determine whether miR-29a/b expression was altered in the pathogenic Th17 
(23) cells, accounting for the upregulation of IFNγ, Tbet and Eomes, we polarized naïve 
CD4+ T cells in presence of TGFβ to generate Th17 (TGFβ) cells or IL-23 to generate 
Th17 (23) cells. We observed a significant decrease in miR-29a/b expression under Th17 
(23) cell polarization compared to Th17 (TGFβ) cells (Figure 9A). Moreover, Tbet and 
Eomes were overexpressed in Th17 (23) cells (Figure 9B). Using flow cytometry to 
assess the production of IL-17a and IFNγ in Th17 (TGFβ) and Th17 (23) cells, we found 
high levels of IL-17a expression under both polarizing conditions. Surprisingly, we did 
not observe increased production of IFNγ in polarized Th17 (23) cells even when Tbet 
and Eomes expression is high (Figure 9C). Therefore, miR-29 expression is differentially 
regulated between Th17 (TGFβ) and Th17 (23) cells. 
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 We next assayed whether STAT3 influences the differential expression of the 
miR-29a/b cluster under Th17 (TGFβ) and Th17 (23) cell polarizing conditions. 
Following analysis of the publically available dataset (Durant et al., 2010; Ghoreschi et 
al., 2010), we found that although a STAT3 peak is present at the Mir29ab locus under 
Th17 (TGFβ) cell polarizing conditions, no such binding of STAT3 is present for Th17 
(23) cells (Figure 9D, top panel). The ability of STAT3 to bind to the Il21 promoter under 
both conditions (Figure 9D, lower panel) suggests that the STAT3-miR-29 axis is 
impaired in Th17 (23) cells. This impaired STAT3-miR-29 axis may account for the 
increased Tbet and Eomes expression in Th17 (23) cells. 
 Due to the enhanced Tbet and Eomes expression of Th17 (23) cells compared to 
Th17 (TGFβ) cells, we decided to overexpress miR-29a in Th17 (23) cells to examine 
whether miR-29 alone can decrease these transcription factors’ expression. The 
introduction of a miR-29a GFP-retrovirus (rv) during Th17 (23) conditions corrected the 
aberrant Tbet expression and partially reduced Eomes expression when compared to 
Th17 (23) cells transduced with GFP-rv (Figure 9E). Furthermore, the level of Tbet 
expression in Th17 (23) cells transduced with miR-29a GFP-rv was comparable to Th17 
(TGFβ) differentiated cells. As such, the forced expression of miR-29a in Th17 (23) cells 
is sufficient to reduce Tbet and Eomes expression. 
	   45	  
 
 
Figure 9. A STAT3-miR-29 axis in polarized Th17 cells in the presence of IL-23 and 
absence of TGFβ. RT-qPCR analysis of (A) miR-29a and miR-29b expression and (B) 
T-bet and Eomes expression from Th17 (TGFβ) and Th17 (23) polarized cells. (C) 
Phenotypic analysis of CD4+CD44+ Th17 (23) cells (left panel) and Th17 (TGFβ) cells 
(right panel) depicting IFNγ and IL-17a expression by flow cytometry. (D) Genome 
Browser screen shots from ChIP-seq experiments showing STAT3 binding sites on 
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Mir29ab and Il21 loci in Th17 (TGFβ) and Th17 (23) cells. (E) Differential expression of 
Tbet and Eomes in Th17 (TGFβ) and Th17 (23) cells when transduced with miR29a 
GFP-rv or GFP-rv. The relative miRNA expression was normalized to U6 and the 
relative mRNA expression was normalized to Gapdh. For this experiment, cells were 
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3.6 Overexpression of miR-29a GFP-rv in Th17 (23) cells reduces Th17 
pathogenicity  
 Given that the transduction of Th17 (23) cells with miR-29a GFP-rv reduced the 
altered Tbet expression and partially decreased Eomes expression, we tested the 
pathogenicity of these miR-29a GFP-rv transduced Th17 (23) cells in an adoptive transfer 
model of EAE. For this purpose, we transduced TCR transgenic (2D2) T cells that are 
specific for myelin oligodendrocyte glycoprotein with either miR-29a GFP-rv or GFP-rv 
under Th17 (23) polarizing conditions. GFP+ cells were then isolated via FACS and 
adoptively transferred to Rag2 deficient mice (Figure 10A). After the onset of disease, we 
found that mice given miR-29a GFP-rv transduced Th17 (23) cells had less disease 
progression when compared to mice given GFP-rv Th17 (23) cells (Figure 10B). These 
findings suggest that overexpression of miR-29a halts disease pathogenicity of Th17 (23) 
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Figure 10. miR-29 overexpression reduces the pathogenicity of Th17 (23) cells. (A) 
Schematic of a passive model of EAE using T cells from 2D2 TCR transgenic mice to 
initiate the onset of disease. (B) EAE clinical score denoting disease progression from 
Rag2 KO mice that were given either miR-29 GFP-rv or GFP-rv transduced Th17 (23) 
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3.7 Summary of Findings 
Although several studies have shown critical roles of miRNA in the 
differentiation and function of CD4+ Th cells (Baumjohann and Ansel, 2013), the  
mechanism(s) controlling miRNA expression in these cells remains unknown. We aim to 
understand the transcriptional networks involved in regulating miRNA in CD4+ Th cells 
and find that STATs have a critical role in this process (Figure 5A-C). Furthermore, our 
analysis of STAT3 in Th17 cell differentiation uncovers the necessary role for STAT3 in 
upregulating miR-21, miR-155 and miR-29a/b expression in Th17 cells (Figure 5C, D 
and G). We also find that the Th17 transcriptional network binds to the miRNA genes, 
Mir155 and Mir29ab (Figure 6A-B) to promote Th17 development. 
Based on our observation of a direct STAT3-driven regulation of miR-29/b 
expression in Th17 cells, we further explore the role of miR-29 in repressing Th1 cell 
associated genes in Th17 and iTreg cells. We find that Th17 and iTreg cells deficient in 
STAT3 have a dramatic decrease in miR-29a and miR-29b expression (Figure 5D and 
8D), suggesting that failure to induce miR-29a/b expression is accompanied by an 
increased expression of Tbet, Eomes and IFNγ. Our data indicates that STAT3 enhances 
miR-29a/b expression in order to repress Th1 cell associated genes, thereby eliminating a 
Th1 cell fate in Th17 and iTreg cells. To this extent, we are interested in generating a 
miR29a/b KO mouse to determine if the absence of miR-29 results in increased 
expression of IFNγ in Th17 and iTreg cells. This line of experimentation may have 
implications for the role of miR-29 in the development of autoimmune disease.  
Furthermore, we find that the pathogenicity of Th17 (23) cells can be alleviated in 
vivo by the over-expression of a single miRNA (Figure 10B). We need to next examine 
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whether the decrease in disease severity by the introduction of miR-29a is the result of 
decreased Tbet and Eomes expression leading to the attenuation of IFNγ producing Th17 
cells. In a model of autoimmune colitis, a higher proportion of IFNγ+ CD4+ T cells were 
recovered from spleens of mice after adoptive transfer of STAT3 KO T cells (Durant et 
al., 2010). It would be of interest to determine whether miR-29 also governs abberant 
IFNγ production in this model. Genome-wide association studies have identified 
polymorphisms in the IL23R, JAK2 and STAT3 genes associated with increased 
susceptibility to Inflammatory Bowel Disease (IBD) (Barrett et al., 2008; Duerr et al., 
2006). As such, it would again be of interest to examine if polymorphisms in the Mir29ab 
gene are also associated with IBD and potentially other autoimmune diseases. 
In summary, our strategy examining a requirement for STAT4, STAT6 and 
STAT3 in miRNA expression led us to find critical roles for STATs in regulating the 
expression of miRNAs. These data contribute to the understanding of STATs in 
regulating miRNA expression and the function of miRNAs in the differentiaiton of CD4+ 
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Chapter 4: The intricate network of transcription factors, microRNA 
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4.1 Determining the mechanism behind the regulation of Th17 cells by miR-155 
Transcriptional and epigenetic programs initiated within CD4+ T cells must work 
together to promote changes in gene expression, ultimately resulting in production of Th 
subset signature cytokines (Ciofani et al., 2012; Kanno et al., 2011; Yosef et al., 2013a). 
miRNA provide a layer of post-transcriptional gene expression in addition to the more 
classical transcriptional networks. Recently, the transcription factor network necessary 
for Th17 cell differentiation was determined (Ciofani et al., 2012). However, the role of 
miRNAs and chromatin regulators in association with this intricate transcriptional 
network is still lacking. 
 In this project, we performed unbiased transcriptomic analyses comparing 
wildtype (WT) and miR-155 knock-out (KO) Th17 cells and found Jarid2 to be 
upregulated in the absence of miR-155. Jarid2 was discovered to be essential for the 
recruitment of PRC2 to genomic sites in embryonic stem (ES) cells (Herz and Shilatifard, 
2010; Li et al., 2010; Peng et al., 2009; Shen et al., 2009). However, the function of 
Jarid2 in adult somatic cells such as lymphocytes is not known. Analysis of Jarid2-
deficient CD4+ T cells allowed us to identify direct targets of PRC2 in Th17 cells. 
Furthermore, deletion of Jarid2 in the miR-155 KO CD4+ T cells results in rescue of 
Th17 cytokine expression and partial rescue of Treg cells. Thus, we demonstrate that 
miR-155 and Jarid2 form a regulatory circuit that can control lineage specific gene 
expression in Th17 and Treg cells through its effect on Polycomb recruitment.  Finally, 
we propose an integrated model for miR-155 and Jarid2 in the regulatory network for 
Th17 cell fate specification. 
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4.2 miR-155 is required for the proper expression of Th17 cytokines 
To determine whether miR-155 plays a cell autonomous role in CD4+ T cells in 
vivo, we generated mixed bone marrow (BM) chimeras and examined miR-155 KO and 
WT CD4+ T cells within the same host (Figures 11A-B).  
 
 
Figure 11. miR-155 KO and WT mixed bone marrow (BM) chimeras. (A) Schematic 
of mixed BM chimera experiment. (B) FACS analysis of miR-155-/- (CD45.2+) and miR-
155+/+ (CD45.1+) cells from the mesenteric lymph node (MLN) of mixed BM chimera 
and the corresponding percentages of total lymphocytes that are either CD45.2+ or 
CD45.1+after reconstitution. 
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We studied a population of Th17 cells present in the mesenteric lymph nodes 
(MLN) of these mixed BM chimeras. Flow cytometry on restimulated 
CD4+TCRβ+CD44+ T cells from the MLN revealed a deficit of cytokine-producing 
RORγt+IL-17a+ Th17 cells among the miR-155 KO population compared to WT (Figures 
12A-B). No significant change in RORγt+IL-17a– Th cells that have undergone lineage 
specification was observed. We also found a cell autonomous defect in the production of 
both IL-17a and IL-22 by miR-155 KO CD4+ T cells upon restimulation ex vivo (Figures 
12C-D). Therefore, CD4+ T cells deficient in miR-155 display cell intrinsic defects in 
Th17 cytokine expression.  
Previously, miR-155 KO CD4+ T cells were reported to have a defect in IFNγ and 
IL17A expression following H. pylori infection (Oertli et al., 2011). To address the role 
of miR-155 in Th1 and Th17 development, we employed the murine model of peroral 
Toxoplasma gondii infection, which is known to induce a highly polarized Th1 effector 
population as well as a localized Th17 response in the small intestine (Liesenfeld, 2002). 
Analysis of CD4+TCRβ+CD44+ T cells in the lamina propria of the small intestine (siLP) 
revealed a cell intrinsic defect in IL-17a and IL-22 production among the miR-155 KO 
population upon restimulation (Figures 12E-F). However, we found comparable IFNγ 
production by both WT and miR-155 KO cells (Figures 12G-H). These data demonstrate 
that miR-155 is specifically required for Th17 cytokine expression, but dispensable for 
the antigen-specific Th1 cytokine response upon peroral infection of T. gondii. 
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Figure 12. Th17 requirement of miR-155. (A) FACS analysis, (B) percentages and 
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absolute cell numbers of miR-155+/+ (CD45.1+) or miR-155-/- (CD45.2+) 
CD4+TCRβ+CD44+ cells in the MLN of mixed BM chimeras to enumerate IL-17a and/or 
RORγt expressing cells (n=5). (C) FACS analysis, (D) percentages and absolute cell 
numbers of CD4+TCRβ+CD44+ cells that express IL-17a and/or IL-22 among WT and 
miR-155 KO cells in the MLN of mixed BM chimeras (n=5). (E,F) FACS analysis (E) 
and absolute cell numbers (F) of CD4+TCRβ+CD44+ cells that express IL-17a and/or IL-
22 in the siLP of mixed BM chimeras from Toxoplama infected mice. (G,H) FACS 
analysis (G) and absolute cell numbers (H) of CD4+TCRβ+CD44+ cells that express CD44 
and IFNγ in the MLN of mixed BM chimeras from Toxoplama infected mice. Statistical 
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4.3 miR-155 is preferentially expressed in mouse and human Th17 cells 
Due to the defect in Th17 cells, we hypothesized that miR-155 may be 
differentially expressed among CD4+ T cell subsets. We found high expression of miR-
155 in both the mouse and human Th17 cultures relative to Th1, Th2, Th17 or TGFβ-
induced Treg (iTreg) cells (Figures 13A-B). The expression of miR-155 increased over 
time during polarization of both primary mouse and human Th17 cultures (Figures 13C-


















Figure 13. Th17-specific expression of miR-155. (A-D) RT-qPCR analysis of mature 
miR-155 expression normalized to U6 snRNA levels from the indicated mouse (A) or 
human (B) CD4+ T cell subsets in vitro polarized or during mouse (D) and human (D) 
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4.4 IL-1β  can rescue IL-17a defect in miR-155 deficient Th17 cells 
 To investigate the mechanism of action for miR-155, we polarized CD4+ T cells 
from miR-155 KO mice and littermate controls towards the Th17 cell fate as previously 
described with IL-6 and TGFβ cytokines (Korn et al., 2007; Nurieva et al., 2007; 
Veldhoen et al., 2006). Since IL-1β promotes the in vivo development of Th17 cells 
(Ben-Sasson et al., 2009; Chung et al., 2009; Shaw et al., 2012), we also tested the effects 
of adding or withholding exogenous IL-1β to Th17 cultures (±IL-1β). Differentiating 
miR-155 KO Th17 cultures without exogenous IL-1β resulted in reduced IL-17a 
production as has previously been reported (O'Connell et al., 2010) (Figure 14A). 
Importantly, we found that miR-155 KO Th17 cultures (- IL-1β) can generate RORγt+IL-
17a- T cells, but they have a defect in producing IL-17a upon restimulation, similar to our 
results in our in vivo mixed BM chimera study (Figure 14A). This defect can be rescued 
upon addition of exogenous IL-1β to our differentiation conditions (Figure 14B). 
However, without exogenous IL-1β, we found decreased expression of Il17a, Il17f, Il1r1, 
and Il22 transcripts in miR-155 KO Th17 cultures compared to WT (Figure 14C). Except 
for Il22, all of these miR-155 dependent gene expression defects were rescued by adding 
IL-1β to our cultures (Figure 14D). We hypothesize that IL-1 signaling is bypassing the 
miR-155 regulation of IL-17 expression by inducting a factor that promotes this cytokine 
expression. 
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Figure 14.	  IL-1 signaling can partially rescue gene expression defects in miR-155 
KO Th17 cells. (A,B) FACS analysis and percentages of CD4+CD44+ T cells expressing 
IL-17a and RORγt in miR-155 KO or WT Th17 cultures polarized (A) without or (B) 
with exogenous IL-1β. (C,D) RT-qPCR analyses of Il17a, Il17f, Il1r1, and Il22 in miR-
155 KO or WT Th17 cultures polarized (C) without or (D) with IL-1β. Relative 
expression was calculated by normalizing to Gapdh. Statistical significance was 
determined using Student’s t test (* p<0.05, ** p<0.01 and **** p<0.0001). 
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4.5 Repression of IL-22 expression in miR-155 KO Th17 cultures occurs at the 
transcriptional level 
 To systematically determine the consequences of miR-155 deletion on gene 
expression, we conducted RNA-seq of miR-155 KO and WT Th17 cultures (+ IL-1β). As 
a result, we found 553 and 551 transcripts that are up- and down-regulated respectively in 
miR-155 KO Th17 cultures compared to WT controls (Figure 15A). In the absence of 
miR-155, the known Th17-associated transcription factors and the IL-17 cytokines were 
unaffected (Figure 15A). However, RNA-seq revealed that expression of Il22, Il10 and 
Il9 are reduced in miR-155 KO Th17 cultures (Figures 15A-B). 
We first focused on Il22 gene expression because it was the most differentially 
expressed transcript between miR-155 KO and WT Th17 cultures. IL-22 production 
could be regulated at multiple levels, including transcriptional regulation through 
transcription factors or epigenetic modification and miRNA mediated post-transcriptional 
regulation. To measure recently transcribed Il22, we performed RT-qPCR of unspliced 
transcripts using primers that amplified an intron of Il22, and found that it was 
significantly decreased in miR-155 KO Th17 cultures compared to WT (Figure 15C). 
Due to the reduction in transcripts observed, we next performed chromatin 
immunoprecipitation (ChIP) of RNA polymerase (pol) II at the Il22 transcriptional start 
site (TSS) to assess promoter accessibility. There was decreased occupancy of Pol II at 
the IL-22 TSS in the absence of miR-155 (Figure 15D). Furthermore, we also found a 
reduction in H3K4me3 at the IL-22 promoter, another indication that the Il22 promoter is 
less active in miR-155 KO Th17 cells (Figure 15E). Taken together, our data are 
consistent with a reduction in Il22 transcription in miR-155 KO Th17 cultures. 
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Given the above results, we hypothesized that miR-155 is targeting a 
transcriptional repressor of Il22. We considered c-Maf as a reasonable candidate, since it 
was previously reported as a target of miR-155 as well as a repressor of Il22 transcription 
(Rodriguez et al., 2007; Rutz et al., 2011). Indeed, we observed a 2.4 fold up-regulation 
of c-Maf protein by Western analysis, (Figure 15F). In contrast, SHIP1 and SOCS1, other 
known miR-155 targets (Lu et al., 2009; O'Connell et al., 2009), were not differentially 
expressed (Figure 14F). Thus, we considered c-Maf as a viable miR-155 target in Th17 
cells. 
ChIP-seq was conducted in miR-155 KO and WT Th17 cells to map the locations 
of c-Maf binding to the genome. In total, we identified about 12,554 and 8,815 c-Maf 
peaks in WT and miR-155 KO Th17 cells respectively, indicating a loss of c-Maf binding 
in miR-155 KO cells. Although c-Maf is overexpressed in miR-155 KO Th17 cells, we 
unexpectedly found fewer peaks of c-Maf binding to chromatin. Importantly, we 
determined that c-Maf failed to bind to the Il22 locus in miR-155 KO Th17 cultures 
(Figure 15G), although it can bind in WT. We did not observe a difference in c-Maf 
binding to the control Il17a locus in miR-155 KO cells under these culture conditions 
(Figure 15G).  All ChIP-seq findings were validated by qPCR (Figure 15H). These 
findings indicate that another transcriptional repressor is responsible for directly silencing 
Il22 in the absence of miR-155, as c-Maf does not bind there.  
Since aryl hydrocarbon receptor (AHR) plays a critical role in Il22 transcription 
(Veldhoen et al., 2008), we assessed whether stimulating AHR activity could rescue Il22 
expression in miR-155 KO Th17 cells. We found that upon ligation of AHR by an 
agonist, 6-formylindolo[3,2-b]carbazole (FICZ), the expression of Il22 is increased, but 
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still impaired in miR155 KO Th17 cells compared to WT (Figure 15I). In contrast, the 
canonical AHR target, Cyp1a1, was not differentially regulated in miR-155 KO and WT 
Th17 cultures with or without FICZ treatment (Figure 15I). These results suggest that 
AHR activity is specifically inhibited at the Il22 locus and may contribute to the inability 
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Figure 15. RNA-seq of miR-155 KO and WT Th17 cells identifies altered cytokine 
expression and putative miR-155 targets. (A) Scatter plot of gene expression for 
20,096 RefSeq transcripts in miR-155 KO and WT Th17 cultures measured by RNA-seq. 
Notable transcription factors and cytokines are highlighted. Dashed red lines indicate a 
fold change of 2. (B) Genome browser screenshots of Il22, Il10 and Il9 loci depict RNA-
seq results as normalized coverage tracks in miR-155 KO (red) and WT (blue) Th17 
cultures. (C) RT-qPCR of Il22 intron 4 ± reverse transcriptase (RT) in miR-155 KO and 
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WT Th17 cultures (+IL-1β). (D) ChIP-qPCR of RNA polymerase II (Pol II) at Il22 TSS 
or (E) H3K4me3 at Il22 promoter in miR-155 KO and WT Th17 cultures. (F) Western 
analysis for c-Maf, Socs1 and Ship1 in miR-155 KO and WT Th17 cultures with protein 
expression quantitated using ImageJ and normalized to Tubulin as a control. (G) Genome 
browser screenshots of c-Maf peaks in the Il22 and Il17a loci in miR-155 KO (red) and 
WT (blue) Th17 cultures. Arrows mark the regions validated by ChIP-qPCR. (H) 
Enrichment of Il22 and Il17a promoter was measured by ChIP-qPCR of c-Maf in miR-
155 KO or WT Th17 cultures. (I) Relative expression of Il22 and Cyp1a1 mRNA 
normalized to Gapdh was determined by RT-qPCR in miR-155 KO or WT Th17 cultures 
(+ IL-1β) and treated with DMSO or 0.3 µM of FICZ. Statistical significance was 
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4.6 Genome-wide analysis of in vitro derived miR-155 KO and WT Th17 cells  
to identify targets of miR-155 in Th17 cells 
 To look for additional potential targets of miR-155, we used the computational 
tool Sylamer, which searches for correlations between gene expression changes in RNA-
seq data and the enrichment of sequence motifs in the 3' UTR of the corresponding genes 
(van Dongen et al., 2008). As a testament to the specificity of this analysis, we found that 
out of the 970 heptameric seed sequences tested, only the two overlapping motifs that 
match the miR-155 seed sequence (AGCATTA and GCATTAA) were significantly 
enriched in genes up-regulated in cells from miR-155 KO compared to WT Th17 cultures 
(Figure 16A). Sylamer analysis revealed 220 transcripts up-regulated in miR-155 KO 
Th17 cultures that contain at least one miR-155 seed sequence in their 3' UTR. To further 
narrow down the putative miR-155 targets, we compared our gene list with two 
computational miRNA target prediction methods which invoke evolutionary 
conservation: TargetScan and PicTar (Krek et al., 2005; Lewis et al., 2003) (Figure 16B). 
In conclusion, we used the signature of miR-155 mediated tuning within the 
transcriptome of Th17 cultures and identified a list of 15 candidates for further testing. 
Our hypothesis that miR-155 is targeting a transcriptional repressor of Il22 led us 
to further investigate PRC2 complex member Jarid2 (Figure 16B). Jarid2 was recently 
shown in mouse ES cells to recruit the histone modifying holoenzyme PRC2 to specific 
sites in the genome and silence transcription of its target genes through H3K27 
trimethylation by Ezh1or Ezh2 (Li et al., 2010; Pasini et al., 2010; Peng et al., 2009; Shen 
et al., 2009). Jarid2 was previously validated to be a target of miR-155 in chicken and 
human cells (Bolisetty et al., 2009). Furthermore, it was demonstrated by high-
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throughput sequencing of RNA isolated by crosslinking and immunoprecipitation (HITS-
CLIP) that Argonaute2 (Ago2), a key protein of the miRNA-induced silencing complex 
(miRISC), directly binds to the upstream predicted site in the 3' UTR of Jarid2 in 
activated WT CD4+ T cells (Loeb et al., 2012). Notably, we found that Jarid2 transcript 
and protein levels are both up-regulated in miR-155 KO Th17 cultures by about two-fold 
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Figure 16. Jarid2 is a miR-155 target in CD4+ Th cells. (A) Sylamer analysis of miR-
155 KO and WT Th17 RNA-seq is depicted as a landscape plot: hypergeometric 
significance values for enrichment of heptamers among 3' UTRs of genes (y-axis) and 
genes sorted from most up-regulated in miR-155 KO to down-regulated (x-axis). Two 
heptameric motifs are significantly enriched in genes up-regulated in miR-155 KO Th17 
cultures (red and orange lines). The horizontal dotted red line represents an E-value 
threshold of P < 0.01 (Bonferroni-corrected for multiple testing). Vertical dotted lines 
indicate log2 fold change cutoffs of differentially expressed transcripts. (B) Comparison 
of our gene list from Sylamer analysis with predictions from TargetScan and Pictar, 
shows an overlap of 15 genes with putative miR-155 binding sites. (C) Relative 
expression of Jarid2 mRNA was determined by RT-qPCR in miR-155 KO or WT Th17 
cultures (+ IL-1β). (D) Western blot analysis of Jarid2 protein in miR-155 KO and WT 
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Th17 lysates quantified using ImageJ and Tubulin as a loading control. (E) Relative 
expression of Jarid2 mRNA in Treg cells was determined by RT-qPCR in miR-155 KO 
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4.7 The epigenome of miR-155 KO Th17 cells is reprogrammed by Jarid2 and PRC2 
 To determine whether Jarid2 may be directly responsible for silencing Il22 
transcription in miR-155 KO Th17 cultures, we conducted ChIP-seq analyses. We found 
increased association of Jarid2 with the Il22 locus in miR-155 KO cells (Figure 17A) and 
validated enrichment by qPCR at three locations (Figure 17B). As predicted, since we do 
not observe differential expression of IL-17a under these culture conditions, Jarid2 did 
not preferentially bind to the Il17a promoter in miR-155 KO Th17 cultures, and serves as 
a negative control (Figure 17B). To determine whether Jarid2 silences Il22 expression by 
recruiting PRC2, we conducted ChIP-seq for Suz12, a core component of the PRC2 
holoenzyme (Figure 17A). Similar to the analyses with Jarid2, Suz12 ChIP confirmed 
increased association of Suz12 with the Il22 locus (Figure 17C), but not at the Il17a 
promoter (Figure 17C), in the absence of miR-155. Next, we examined whether there was 
increased H3K27 trimethylation at the Il22 locus; higher occupancy of H3K27me3 was 
found at the IL-22 locus (Figures 17A and 17D), but not at the Il17a promoter (Figure 
17D), in miR-155 KO Th17 cultures. 
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Figure 17. Jarid2 recruits PRC2 to epigenetically silence the Il22 locus in absence of 
miR-155. (A) Genome browser screenshots depict Jarid2, Suz12, and H3K27me3 
enrichment at the Il22 locus. Arrows indicate promoter, proximal, and distal regions 
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validated by qPCR. (B) Enrichment of anti-Jarid2, (C) anti-Suz12, and (D) anti-
H3K27me3 along with control IgG ChIPs of miR-155 KO and WT Th17 cultures at three 
indicated locations within Il22 locus or the Il17a promoter was determined by qPCR. 
Validations were normalized to input controls and results are representative of three 
independent experiments with statistical significance determined using unpaired 
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 Since the direct targets of PRC2 in CD4+ T cells have not been systematically 
examined, we performed ChIP-seq analyses for Jarid2, Suz12, and H3K27me3 in miR-
155 KO Th17 cultures and WT controls. Our analysis identified 6,786 and 4,070 Jarid2 
islands, 13,206 and 14,862 Suz12 islands, and 4,495 and 4,335 H3K27me3 islands in WT 
and miR-155 KO Th17 cells respectively (Figure 18A). Correlating with the increased 
Jarid2 expression observed, we found augmented Jarid2 islands as well as Suz12 and 
H3K27me3 islands when comparing the miR-155 KO to WT Th17 cells (Figure 18A). To 
find genes that are directly targeted by PRC2, we looked for Jarid2, Suz12, and 
H3K27me3 islands increased in miR-155 KO Th17 cultures that were co-localized ± 10 
kb from a gene body (Figure 18A). This list included canonical PRC2 target genes, such 
as the HoxA gene clusters (Figures 18B). We also found that PRC2 targeted SCL/Tal1, a 
transcription factor gene essential for the specification of hematopoietic stem cells 
(HSCs) that is silenced upon differentiation (Figure 18C). In summary, we found that 
Jarid2 up-regulation in miR-155 KO Th17 cells resulted in widespread increased 
recruitment of the Jarid2-PRC2 holoenzyme at specific sites throughout the genome that 
coincided with increased deposition of H3K27me3. 
In addition to Il22, we found that other genes were upregulated; Il10 and Il9, were 
also directly targeted by the Jarid2-PRC2 holoenzyme (Figures 18D-E). Furthermore, this 
analysis identified genes not yet described as playing a role in Th17 differentiation such 
as Activating Transcription Factor 3 (ATF3), a member of the AP-1 superfamily of 
leucine zipper proteins that includes Fos, Jun and BATF. Atf3 is differentially targeted by 
Jarid-PRC2 in miR-155KO and WT Th17 cells (Figure 18F), closely resembling what is 
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observed for the Th17 cytokines genes. Thus, miR-155 and Jarid2 in Th17 cells may 
regulate Atf3. 
Figure 18. Jarid2 recruits PRC2 to reprogram the epigenome of miR-155 KO Th17 
cells.  (A) Tables summarize Jarid2, Suz12 and H3K27me3 ChIP-seq experiments in 
miR-155 KO and WT Th17 cultures. First column is total number of peaks in miR-155 
KO and WT identified using SICER 3.1. Second column indicates the number of peaks 
affected (either↑or↓) in miR-155 KO compared to WT controls using SICER 3.3.1. Third 
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column indicates the number of RefSeq genes within 10 kb of the peaks in question from 
SICER 3.3.1. (B-F) Genome browser screenshots depict Jarid2, Suz12, and H3K27me3 
enrichment at the HoxA cluster (B), Tal1 (C), Il10 (D), Il9 (E) and Atf3 (F) loci as a result 
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4.8 IL-17a expression defect in miR-155KO Th17 cells is rescued by ATF3 
To determine if Atf3 is regulated by miR-155 in Th17 cells, we assayed the 
expression of Atf3 in miR-155 KO and WT Th17 cells by RT-qPCR. We found increased 
expression of Atf3 in absence of miR-155 when compared to controls (Figure 19A). Since 
the role of Atf3 in Th17 cells is currently unknown, we used a GFP-rv vector to 
overexpress Atf3 (ATF3-rv) during Th17 differentiation. We found that Th17 cultures 
transduced with ATF3 expressed greater levels of IL-17a compared to empty virus 
control (GFP-rv) (Figure 19B). To investigate if ectopic expression of ATF3 rescues the 
IL-17A defect in miR-155 KO Th17 cells, we overexpressed ATF3 in miR-155KO Th17. 
We found that miR-155KO T cells transduced with ATF3 are able to augment their IL-
17a production when compared to untransfected controls (Figure 19C). In summary, Atf3 















 Figure 19. ATF3 promotes IL-17a expression and rescues the IL-17a defect in miR-
155KO Th17 cells. (A) Relative expression of Atf3 mRNA by RT-qPCR of miR-155 KO 
and WT Th17 cells. (B) Histogram depicts IL-17a expression from FACS analysis of 
Th17 cultures transduced with ATF3-rv (ATF3 GFP-rv) or empty vector (GFP-rv) and 
gated on transduced CD4+CD44+GFP+ cells; (C) miR-155 KO Th17 cultures transduced 
with ATF3-rv and gated on transduced (GFP+) or untransduced (GFP-) CD4+CD44+ cells. 
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4.9 Conditional deletion of Jarid2 in CD4+ T cells 
The miR-155 KO mouse allowed us to assess Th17 development in the context of 
Jarid2 increased expression. To determine the direct contribution of Jarid2 during Th17 
differentiation, we generated Jarid2fl/fl;CD4-cre mice (Figure 20A-C). These mice delete 
Jarid2 in T cells at the double positive T cell stage. Therefore all periphernal T cells are 
essentially KO for Jarid2. We performed ChIP-exo, a variant of ChIP-seq that uses 
lambda 5'-3' exonuclease to reduce background and increase resolution of the assay 
(Rhee and Pugh, 2012). We found that in the absence of Jarid2, genomic recruitment of 
Suz12 was diminished.  As examples, we show the Hoxa and Hoxd clusters, Il22 and Atf3 
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Figure 20. Jarid2 conditional targeting in CD4+ T cells. (A) Schematic of Jarid2 
conditional targeting. In this conditional allele, exon 3 is flanked by loxP sites in a 
strategy that is essentially identical to a previously published allele of Jarid2 (Mysliwiec 
et al., 2006; Shen et al., 2009). (B) RT-qPCR across targeted exon 3 from Jarid2-/- 
(Jarid2fl/fl; CD4-cre) and littermate controls. Relative expression was found by 
normalizing to Gapdh mRNA. (C) Jarid2 western blot of Jarid2 KO (Jarid2-/-) and WT 
(Jarid2+/+) Th17 cultures. (D-G) Genome browser screenshots of the HoxA cluster (D), 
HoxD cluster (E), Il22 (F), and Atf3 (G) from the ChIP-exo of Suz12 in WT and Jarid2 
KO (Jarid2-/-) Th17 cultures.  
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Furthermore, we differentiated CD4+ T cells from Jarid2 fl/fl;CD4-cre mice and 
littermate controls toward the Th17 cell fate and found a significant increase in IL-17a 
expression upon Jarid2 ablation (Figures 21A-B). Jarid2-deficient Th17 cells did not 
aberrantly express IFNγ (Figure 21A). To further assess gene expression changes in the 
absence of Jarid2, we performed RT-qPCR and found Il17a, Il17f, Il22, Il10, Il9 and Atf3 
transcripts to be increased in Jarid2-deficient Th17 cultures (Figures 21C-D). In contrast, 
we did not observe changes in expression of RORγt, IRF4 and BATF in Jarid2-deficient 
Th17 cultures compared to WT (Figures 21C). Furthermore, we measured cytokine 
concentrations in Th17 cultures and found increased IL-22, IL-10 and IL-9 protein in 
absence of Jarid2 (Figure 21E). We found that H3K27me3 deposition is decreased at the 
promoters of Il22, Il10, and Il9 upon Jarid2 ablation (Figure 21F). Moreover, we found 
augmented levels of unspliced message for Il22 and Il9 in Jarid2-deficient Th17 cultures 
suggesting increased transcription of these cytokine genes (Figure 21G). Thus, lack of 
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Figure 21. Absence of Jarid2 in CD4+ T cells results in enhanced Th17 development. 
(A) FACS analysis of IL-17a and IFNγ expression in CD4+CD44+ cells from Jarid2fl/fl; 
CD4-cre mice and littermate controls cultured under Th17 polarizing conditions without 
IL-1β and (B) the corresponding percentages of CD4+CD44+IL-17a+ T cells. (C) Relative 
expression of Il17a, Il17f, Atf3, Rorc, Irf4, Batf mRNA by RT-qPCR from WT and 
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Jarid2-deficient Th17 cultures. (D) Relative expression of Il22, Il9 and Il10 mRNA in 
Jarid2 KO and WT Th17 cultures was determined by RT-qPCR. (E) Cytokine 
concentrations in supernatant of Th17 cultures were determined by ELISA. (F) 
H3K27me3 at promoters of Il22, Il10, Il9 and Hprt determined by ChIP-qPCR. (G) RT-
qPCR of Il22 intron 4 and Il9 intron 3 of Jarid2 KO and WT Th17 cultures ± reverse 
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4.10 Conditional ablation of Jarid2 partially rescues Th17 and Treg cells in miR-155 
KO 
To determine whether the Th17 and Treg phenotypes observed in miR-155 KO 
mice are caused by increased expression of Jarid2, we generated double KO (DKO) mice 
wherein Jarid2 is conditionally deleted at the DP stage in the T cell lineage of miR-155 
KO mice. We made mixed BM chimeras of WT (CD45.1+) and DKO (CD45.2+) cells, 
and infected them with T. gondii to assess IL-17a and IL-22 expression as well as Treg 
homeostasis. Remarkably, DKO Treg cells are competitive with WT Treg cells whereas 
miR-155 KO Treg cells failed to compete with either DKO or WT Tregs (Figure 22A). In 
addition, development of CD4+IL-17A+ T cells is restored in the DKO, although IL-22 
expression was not rescued (Figure 22B).  Thus, we can partially rescue Foxp3+ cells and 
IL-17a expression in vivo upon ablation of Jarid2 in miR-155 KO T cells (Figures 22C-
E). We recapitulated the rescue of Il17a and Il17f expression in vitro with DKO Th17 
cultures (Figure 22F). Furthermore, through analysis of Jarid2 heterozygous conditional 
KOs we found that loss of one allele of Jarid2 in miR-155 KO Th17 cells is sufficient to 
reduce Jarid2 protein levels to near WT levels (Figure 22G) and to rescue IL-17a 
expression (Figures 22H-I). 
Since deletion of Jarid2 in miR-155 KO CD4+ T cells did not rescue Il22 
expression, we hypothesized that in the absence of Jarid2, the chromatin structure at the 
Il22 promoter is now in a permissive state to allow binding of other transcription factors. 
We focused our investigations on c-Maf, a known repressor. Indeed, in DKO Th17 
cultures, we now observe c-Maf binding at the IL-22 promoter by ChIP-seq 
analysis(Figure 22J). Globally, the Jarid2-PRC2 holoenzyme may have the ability to 
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dictate where transcription factors such as c-Maf can bind chromatin by reprogramming 
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Figure 22. Epistasis between Jarid2 and miR-155 in Treg and Th17 cells. (A,B) 
FACS analysis of WT, miR-155 KO or miR-155 KO; Jarid2fl/fl; CD4-cre (DKO) cells 
from siLP of infected mixed BM chimeras to enumerate CD4+TCRβ+CD44+ cells that are 
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IFNγ or Foxp3 positive (A), or IL-17a and/or IL-22 positive (B), 8 days after T. gondii 
infection. (C-E) Indicated percentages of CD4+TCRβ+CD44+ WT, miR-155 KO or DKO 
cells from the siLP of infected mixed BM chimeras. (F) Relative expression of Il17a and 
Il17f mRNA was determined by RT-qPCR in WT, miR-155 KO or DKO Th17 cultures (- 
IL-1β). (G) Western blot analysis of Jarid2 and tubulin protein in WT, miR-155-/- and 
miR-155-/-; Jarid2+/- Th17 cells. (H) Histogram depicts intracellular IL-17a expression 
in WT, miR-155-/- and miR-155-/-; Jarid2+/- Th17 cultures (- IL-1β). (I) The 
corresponding percentages of CD4+CD44+IL-17a+ T cells. (J) c-Maf and IgG ChIP-qPCR 
on the Il22 promoter in WT, miR-155 KO or DKO Th17 cultures normalized to input. 
Statistical significance determined using unpaired Student’s t test (* p<0.05, ** p<0.01, 










	   87	  
4.11 Summary of findings 
We propose a mechanism by which miR-155 regulates the fates of Th17 and Treg 
cells through PRC2 member Jarid2. By regulating the expression of Jarid2 miR-155 can 
indirectly promote gene expression through post-translational inhibition of this known 
repressor. Using high throughput ChIP and RNA-seq approaches, we assessed the 
genome-wide consequences of Jarid2 up-regulation in miR-155 KO Th17 cultures. We 
observe increased recruitment of PRC2 to genomic sites accompanied by increased 
H3K27 trimethylation and silencing of expression of Il22, Il10 and Il9 cytokines involved 
in mediating tissue repair and homeostasis in response to inflammation (Goswami and 
Kaplan, 2011; Ouyang et al., 2011; Zenewicz and Flavell, 2011). Although H3K27me3 is 
often equated with transcriptional silencing, direct perturbation experiments to address 
this relationship are lacking in mammalian systems. Here, we have ablated Jarid2 in 
CD4+ T cells to prevent recruitment of PRC2, the holoenzyme that catalyzes 
trimethylation of H3K27 at its targets.  This allowed us to identify Jarid2-dependent 
PRC2 targets genome-wide and examine the consequences of the lack of Jarid2 on gene 
expression in Th17 cells. Jarid2-deficient CD4+ T cells undergo enhanced Th17 
differentiation in part manifested by up-regulation of Il17a and Atf3. Since reduced or 
excessive H3K27me3 catalysis can affect the efficiency of Th17 differentiation and Treg 
homeostasis, miR-155 may have evolved to modulate PRC2 recruitment by fine-tuning 
Jarid2 expression. 
Thus, we integrate miR-155 and PRC2 to the Th17 transcriptional network 
(Ciofani et al., 2012)(Figure 23). We find that in Th17 cells, the Jarid2-PRC2 complex 
targets genes that can contribute to IL17 expression (Atf3), cellular plasticity genes 
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(Tbx21 and Eomes), and immunoregulatory cytokine expression (Il22, Il10 and Il9). In 
addition to Jarid2, miR-155 appears to repress c-Maf, an important transcription factor in 
Th17 cells. Interestingly, we revealed that Jarid2 can prevent c-Maf binding in the Il22 
promoter through regulation of chromatin accessibility. Additionally, we provide an 
updated view of the complex regulatory network in Th17 cells to exemplify how a 
miRNA and chromatin regulator might interact to orchestrate gene expression programs. 
 Taken together, our study reveals novel aspects of the Th17 regulatory network in 
which miR-155 promotes acquisition of effector functions. By regulating a chromatin 
modifying complex, miR-155 can mediate global gene expression changes. A two-fold 
change in Jarid2 expression by a miRNA can reprogram the epigenome of a cell via 
H3K27 trimethylation. How miRNA, transcription factors and chromatin cooperate to 
orchestrate a gene expression program has not been systematically analyzed. Using Th17 
differentiation as a model system, we demonstrate that miR-155 can have profound 
effects on the chromatin landscape and links post-transcriptional, epigenetic as well as 
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Figure 23. An updated Th17 regulatory network that integrates miR-155 and 
Jarid2. The KCRI Th17 cell specification regulatory network (Ciofani et al., 2012) was 
downloaded from http://th17.bio.nyu.edu/pages/cytoscape.html. Targets of miR-155 and 
Jarid2-PRC2 were integrated in to the KCRI network to generate an updated Th17 
regulatory network. Associations between transcription factors and miR-155 were added 
based on available ChIP-seq evidence. Genes (nodes) are colored based on the level of 
differential expression (orange to blue correspond to low to high Th17 expression relative 
to Th0; grey denotes missing expression data). Edges (associations) are colored as either 
activation (green) or repression (red). Nodes with many associations are denoted by large 
circles. Nodes with 4 or more connections are grouped in the middle, whereas those with 
fewer connections are in the periphery. 
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5. Small molecule inhibitor screen to identify targets that alter miR-155 
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5.1 High throughput small molecule screen for inhibitors of miR-155 in Th17 cells 
CD4+ Th17 cells are a subset of CD4+ Th cells that have been implicated in a wide 
variety of autoimmune disorders such as rheumatoid arthritis (Sato et al., 2006), 
inflammatory bowel disease (Barrett et al., 2008), psoriasis (Zheng et al., 2007), and 
multiple sclerosis (Kebir et al., 2007). My research has shown that high expression of 
miR-155 promotes the expression of Th17 cell cytokines. The identification of 
compounds that inhibit miR-155 expression may therefore offer a new approach to 
identify drugs in the treatment of autoimmune diseases. As such, we began collaboration 
with the NIH National Center for Advancing Translational Sciences (NCATS) to identify 
small molecules that inhibit miR-155 expression.  
For this aim, we took advantage of a genetically engineered reporter mouse in 
which lacZ has been inserted into the endogenous Mir155 locus (Thai et al., 2007) and 
began assaying >50,000 small molecules inhibitors that decreased β-galactosidase 
activity following Th17 polarization. We initially focused on a group of biologically 
active compounds and tested seven different concentrations of each compound as well as 
a DMSO control on our miR-155 reporter Th17 cells (Figure 24A-B). The predicted ideal 
profile of a candidate compound from our assay would have been one that decreased β-
galactosidase activity while not affecting cell viability (Figure 24C). Using acurve class 
classification algorithm developed by our collaborations (Inglese et al., 2006), we 
selected those compounds that were high quality inhibitors of miR-155 expression in 
Th17 cells. Upon validation of miR-155 expression levels by RT-qPCR for one 
compound (NCGC00015205) from our preliminary hit, we observed decreased miR-155 
expression upon addition of this compound to in vitro differentiating Th17 cells (Figure 
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24D). These results supported the validity of our robust high throughput screen to test 
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Figure 24. Selection and validation of candidate compounds that inhibit miR-155 
expression in Th17 cells. Scatter plot for (A) one control (DMSO) plate and (B) one 
assay plate from the LOPAC library of biological compounds measuring the Relative 
light unit (RLU) from miR-155 reporter Th17 cells. (C) Predicted dose response curve for 
a compound from the LOPAC library with an ideal profile that antagonizes miR-155 
expression with minimal effect on cell viability. The black line shows miR-155 
expression using the Beta-Glo assay and the blue line shows cell viability measured by 
CellTiter-Glo. (D) Relative expression of Bic/Mir155 by RT-qPCR assay normalized to 
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5.2 NCGC00015205 impairs IL-17a production 
Based on our findings in which NCGC00015205 decreased miR-155 expression 
in Th17 cells, we were further interested in assessing the effect of this compound on 
Th17 cytokine production. For this purpose, we assayed the T cell survival (Figure 25A), 
T cell activation (Figure 25B) and IL-17a expression (Figure 25C) on Th17 cultures 
treated with NCGC00015205 and DMSO controls. We found that while T cell survival 
and activation were not altered in the presence of the miR-155 inhibitor 
(NCGC00015205), the production of IL-17a was impaired (Figure 25). These results are 
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Figure 25. NCGC00015205 decreases IL-17a expression in CD4+ Th17 cells. Flow 
cytometric analysis of in vitro polarized CD4+ Th17 cells treated with either the miR-155 
inhibitor (NCGC00015205) or DMSO (as control) showing: (A) the percentage of live 
cells using a Live/Dead stain; (B) the percentage of activated T cells (CD4+CD44+) gated 
amongst live cells; and (C) the expression of IL-17a amongst activated cells. 
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5.3 Summary of Findings 
 Through collaboration with NIH NCATS, we have identified numerous small 
molecule inhibitors, including (NCGC00015205), that alter miR-155 expression in a high 
throughput screen. Further validation of some of these compounds is still required. 
Validation of NCGC00015205 under Th17 cell culturing conditions resulted in decreased 
miR-155 expression and impaired Th17 cell differentiation (Figure 24D and 25). In terms 
of mechanism, NCGC00015205 is highly selective for TSPO, a peripheral 
benzodiazepine receptor that is localized in the mitochondria. As such, characterization 
of TSPO in Th17 cell differentiation will be necessary to determine how this receptor 
affects miR-155 expression. We plan to identify downstream signaling pathways that are 
altered upon changes in TSPO activity by incorporating different TSPO ligands or TSPO 
knockdown in Th17 cell cultures. Since our goal for this screen was to identify inhibitors 
of miR-155 expression for therapeutic potential, we are interested in testing the 
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6.1 A regulatory network for Th17 development 
The differentiation and reprogramming of CD4+ Th cell lineages are mediated by 
highly orchestrated gene expression programs that require not only activation of specific 
genes necessary for new cell fate decision, but also repression of alternative and 
precursor cell fates. miRNA are evolutionarily conserved, small, non-coding RNA of 
approximately 21-24 nucleotides in length that repress gene expression at a post-
transcriptional level via the endogenous RNA interference pathway (Muljo et al., 2010) 
and have emerged as new regulators of gene expression programs. As such, miRNA can 
cooperate with transcription factors during cellular differentiation by repressing 
unwanted gene expression post-transcriptionally. Based on current estimates, mammals 
have >500 miRNA genes that have the collective potential to target up to 60% of the 
protein-coding transcriptome and thus regulate a large variety of biological processes 
(Friedman et al., 2009). In one striking example, enforced expression of the miR-
302~367 ES cell-specific cluster is sufficient to reprogram somatic fibroblasts to become 
induced pluripotent stem (iPS) cells (Anokye-Danso et al., 2011). 
 By exploiting the well-characterized transcriptional network of CD4+ Th cell 
differentiation with particular focus on the Th17 cell lineage, my graduate research 
investigated the function of miRNA in regulation of CD4+ Th17 cell fate. Based on this 
research, I was able to integrate miR-155, miR-29 and Jarid2 in a regulatory network 
critical for Th17 cell lineage specification and repression of alternative cell fates (Figure 
26). My analysis into the molecular basis of CD4+ Th17 cell differentiation provided the 
opportunity to devise innovative strategies for the targeting of Th17 cytokine expression. 
We have begun to assay and validate potential miR-155 inhibitors that can be used for the 
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treatment of autoimmune diseases and cancer, as both conditions have an over-expression 

















	   100	  
 
 
Figure 26. The interplay between transcription factors, chromatin and miRNA that 
make up a regulatory network to promote CD4+ Th 17 cell development and 
function.  After an initial CD4+ T cell stimulation, STAT3, BATF and IRF4 induce the 
expression of key transcription factors and miRNA genes that drive a CD4+ Th17 cell 
differentiation program. Following induction of RORγt, miR-29 and miR-155 expression, 
further specification towards the Th17 cell lineage continues with the targeting of 
inhibitory molecules such as Jarid2 by miR-155, the targeting of alternate fates by miR-
29 and the initiation of cytokine expression via the Th17 cell transcriptional network. 
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7.1 Appendix: Glossary of Abbreviations 
 Ago  Argonaute 
 APC  Antigen Presenting Cell  
 BM  Bone Marrow 
 ChIP  Chromatin immunoprecipitation  
 ChIP-seq  Chromatin immunoprecipitation followed by massive-parallel  
   sequencing  
 CIA  Collagen Induced Arthrits 
 Cre  Cre recombinase  
 DKO  Double Knock out 
 EAE  Experimental Autoimmune Encephalitis  
 EAU  Experimental Autoimmune Uveitis 
 ELISA  Enzyme-linked immunosorbent assay 
 FACS  Fluorescence-Activated Cell Sorting 
 FC  Fold Change 
 GEO  Gene Expression Omnibus database  
 GFP  Green Fluorescent Protein  
 HIV  Human immunodeficiency virus 
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 IBD  Inflammatory Bowel Disease 
 IL  Interleukin 
 IPEX  immunodysregulation, polyendocrinopathy, enteropathy, X-linked  
   syndrome  
 iTreg  induced regulatory T cell 
 KO  Knock out  
 LincRNA Long intergenic non-coding RNA 
 MACS  Magnetic Activated Cell Sorting 
 miRNA microRNA 
 MLN  Mesenteric Lymph Node 
 MMPs  Matrix metalloproteinases 
 NCATS National Center for Advancing Translational Sciences  
 NCBI  National Center for Biotechnology Information  
 ncRNA non coding RNA  
 PBMCs  Human peripheral blood mononuclear cells  
 PCR  Polymerase Chain Reaction 
 PFA  Paraformaldheyde  
 PMA  Phorbol 12-myristate 13-acetate 
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 PolII  Polymerase II 
 PRC2  Polycomb repressive complex 2  
 RA  Rheumatoid arthritis 
 RNA  Ribonucleic acid  
 RNA-seq RNA sequencing 
 RT-qPCR Real Time quantitative Polymerase Chain Reaction  
 RV  Retro virus 
 siLP  Small intestine Lamina Propria 
 STAT  Signal Transducer and Activator of Transcription  
 Th  T helper cell 
 TGFβ  Tumor Growth Factor beta  
 TCR  T cell receptor 
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